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INTRODUCTION
There is evidence of impaired liver synthetic function 
in Down Syndrome1,2, but the degree to which this 
declines with age is not clear. Hepatitis B infection 
is particularly common in the institutionalised 
learning-disabled population3, and there is evidence 
that individuals with Down Syndrome are more 
vulnerable to such infection than are those with 
other forms of learning disability4. The extent to 
which low serum albumin in Down Syndrome 
patients can be ascribed to chronic viral hepatitis is, 
therefore, not known. 
Pathological changes of Alzheimer’s Disease are 
universal in Down Syndrome patients over the age of 
405, and almost all develop dementia with time. Low 
levels of serum albumin have been reported in Down 
Syndrome, but the confounding effects of viral-
induced liver disease have not been clariﬁed. There is 
reason to suspect that Alzheimer’s Disease, both in 
the presence and in the absence of Down Syndrome, 
may be associated with low serum albumin levels: 
low levels of serum albumin have been reported 
in Alzheimer’s Disease patients without Down 
Syndrome6, and Elovaara7 found low serum albumin 
in patients with Down Syndrome and Alzheimer’s 
Disease compared to age-matched controls.
Clinical differences consequent on low serum 
albumin concentrations in Down Syndrome are only 
likely with profoundly low values: lower oncotic 
pressures and pharmacokinetic changes with the 
use of highly protein-bound drugs, for example. Even 
mild hypoalbuminaemia might, however, provide 
further evidence of cellular dysfunction in this 
syndrome8. If severe, it could have pharmacokinetic 
implications when such patients are exposed to 
highly protein-bound drugs.
Serum albumin in Down Syndrome with and 
without Alzheimer’s Disease
ABSTRACT 
Aims We investigated whether or not serum albumin concentrations in Down Syndrome 
were lower than those of a cohort of similarly moderately- to-severely-disabled 
institutionalised patients without Down Syndrome and, if so, whether or not this 
could be ascribed to the presence of liver disease. We also sought to determine the 
inﬂuence of Down Syndrome, age, liver disease, and Alzheimer’s Disease on the 
serum albumin concentration.
Methods  We performed a cross-sectional study on 205 institutionalised patients with 
Learning Disabilities (47 with Down Syndrome, 158 without), and used multiple 
regression techniques to determine the relative effects of age, liver disease, and 
the presence or absence of Down Syndrome on the serum albumin concentration. 
Among Down Syndrome patients. We also sought to determine the association 
between serum albumin concentration and the presence of Dementia of 
Alzheimer’s Type.
Results  Down Syndrome patients had lower serum albumin levels than non-Down 
Syndrome patients. Serum albumin concentrations declined with age at a similar 
rate in both groups, such that the effect on serum albumin of having Down 
Syndrome was equivalent to an additional 44 years of age. The serum albumin 
concentration in Down Syndrome patients with Alzheimer’s Disease was greater 
than that in Down Syndrome patients without Alzheimer’s Disease. 
Conclusions  Down Syndrome is associated with a low serum albumin concentration, 
independently of the presence of liver disease. The advent of Alzheimer’s Disease in 
Down Syndrome is not associated with a further fall, and may be associated with a 
rise, in serum albumin concentrations.
CS Clarke1, 
FJ Bannon
Dept. of Child & 
Family Therapy, 
Mater Misericordiae 
Hospital, Eccles 
Street, Dublin 7.1
Dept. of Statistics 
& Actuarial Science, 
University College 
Dublin.
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We sought to determine, using a cohort study, 
whether or not serum albumin levels are lower 
in Down Syndrome patients than in a cohort of 
similarly disabled non-Down patients, and whether 
such low serum albumin can be attributed to liver 
disease. We also hypothesised that the occurrence of 
Alzheimer’s Disease in Down Syndrome might affect 
serum albumin concentrations.
MATERIALS AND METHODS
The subjects were all male residential patients in 
St. Mary’s Hospital, Drumcar, Co. Louth, and were 
aged between 15 and 70 years. The experimental 
group comprised all patients with Down Syndrome, 
the control group all patients without Down 
Syndrome in the same hospital who had had tests 
of liver function performed during the same period 
(1999-2002). Both groups had moderate-profound 
mental retardation. There were 47 patients with and 
158 without Down Syndrome. 12 of the patients with 
Down Syndrome had Alzheimer’s Disease and 35 
did not. Blood testing was performed as part of the 
routine assessment of this population with learning 
disabilities. An additional 22 patients did not have 
blood tests for a variety of reasons, and were not 
therefore included in the study. Other causes of 
hypoalbuminaemia, such as malnutrition, protein-
losing enteropathy, and nephrotic syndrome, were 
excluded clinically and, where appropriate, with 
appropriate laboratory investigations. 
Blood samples were drawn on varying occasions 
from 1999 to 2002. Measurements included serum 
albumin and alanine amino-transferase. The 
diagnosis of dementia was made using modiﬁed 
ICD-10 criteria9, supported by two cognitive tests 
(the Down’s syndrome Mental Status Examination 
(DSMSE)10) and the Test for Severe Impairment (TSI)11, 
and two observer-rated questionnaires (the Daily 
Living Skills Questionnaire (DLSQ)12 and the Adaptive 
Behavior Scale – 2nd edition ABS-RC2)13.
The study was approved by the Hospital Ethics 
Committee. U.K. Medical Research Council Guidelines 
on research on the learning disabled14 and on the use 
of personal information in medical research15 were 
followed.
Data Analysis
Some patients having been tested for albumin 
level on a number of occasions over a short period 
of time, an average albumin level for each patient 
was taken. In the analysis, the inﬂuence that each 
patient’s mean albumin level made to the model 
was weighted according to the number of tests 
performed. The more a patient was tested, the more 
accurate the mean value and the greater its inﬂuence 
on the model describing the data. There is a potential 
bias in this situation, however, in that albumin results 
might inﬂuence the decision to test. To outrule this 
bias the number of tests was correlated with the 
albumin level. There was no evidence of a relationship 
(correlation co-efﬁcient = -0.107 (p = 0.1267)), so it 
was possible to using weighting in the analysis.
The effects of age, Down Syndrome, Alzheimer’s 
Disease, and liver disease on serum albumin levels 
were tested using multiple linear regression. Age 
was ﬁtted as a continuous variable, while Down 
Syndrome, Alzheimer’s Disease, and liver disease 
were ﬁtted as categorical variables. Age was tested 
individually with each of the categorical variables 
with linear and quadratic effects and interactions of 
linear and quadratic effects with the class variable in 
question. The F-test was used in the regression sum 
of squares to test the null hypothesis of no difference 
between the two levels of each class variable. The 
coefﬁcient of the age covariate was tested by a t-test, 
and a table of least-square-means was produced 
for each class variable to illustrate the differences 
between levels of class variables. For a particular 
categorical variable, least-square-means represent 
the means of each level of this class variable, 
averaged over the other effects in the model. In the 
case of an interaction, the table of least-square-
means comprises the means of all combinations of 
the class variables involved in the interaction. 
Proc GLM of SAS (which has a facility to ﬁt weighted 
multiple-linear-regression) was used to ﬁt the 
models. The linear regression approach has the added 
advantage that it can handle unbalanced data, that 
is, situations in which the number of patients within 
each combination of categorical variables differs.
RESULTS
Liver Disease in Down Syndrome and non-Down 
Syndrome patients
Sixty-six of 205 patients had liver disease, and there 
was no difference in the prevalence of liver disease 
among patients with and without Down Syndrome 
(Table 1).
Age and albumin concentration
The coefﬁcient of the age covariate was -0.081 
(std. dev. 0.0236 p = 0.0007), the effect of Down 
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Syndrome on serum albumin concentration being 
similar to that of an extra 44 years of age (Figure 1). 
The most parsimonious model ﬁtting the data with 
all signiﬁcant terms was: [albumin] = age, Down 
Syndrome, Alzheimer’s Disease. The only interaction 
that approached signiﬁcance was Down Syndrome 
x liver disease (p = 0.06). Though not signiﬁcant, the 
‘liver disease’ term must be included because of the 
interaction. The coefﬁcient of the age covariate was 
-0.076 (se 0.0236 p = 0.0015). Table 2 shows the s. 
albumin levels in the presence and absence of liver 
disease.
Down Syndrome and albumin concentration
The presence of Down Syndrome had a large effect 
on reducing the albumin level, regardless of age and 
the presence of liver disease (Table 2). 
Alzheimer’s Disease and serum albumin
The presence of Alzheimer’s Disease increased the 
serum albumin concentration, and the difference 
between the two groups (as well as being statistically 
signiﬁcant) was relatively large (2.0 g/l) (Table 2).
DISCUSSION
Our ﬁnding that serum albumin concentrations are 
lower in Down Syndrome than in similarly disabled 
non-Down Syndrome patients is in keeping with 
that of other studies1,2, and supports the theory that 
Down Syndrome is associated with widespread 
organ and tissue dysfunction16. Our clariﬁcation that 
low serum albumin in Down Syndrome is not due to 
hepatitis extends the ﬁndings of previous studies. 
The ﬁnding that serum albumin concentrations were 
signiﬁcantly higher in Down Syndrome patients 
with Alzheimer’s Disease than in those without 
Alzheimer’s Disease is surprising: neither age nor 
liver disease was a confounder, and in no patient was 
there clinical evidence of nephrotic syndrome or a 
protein-losing enteropathy. 
A possible explanation is that nutritional 
supplementation administered to Down Syndrome 
patients who became increasingly disabled with 
dementia reversed the fall in serum albumin. 
Although vitamin and mineral supplements 
were administered to some patients, however, 
none received enteral or parenteral protein 
supplementation, anabolic steroids or any other 
intervention calculated to increase serum albumin 
levels (though the effectiveness of such measures 
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Figure 1 — ALTERATION IN S. [ALBUMIN] WITH AGE - DS VS. NON-DS
Table 2
EFFECTS OF DOWN SYNDROME AND ALZHEIMER’S DISEASE ON SERUM [ALBUMIN]
LS mean SE Mean P-value
Down Syndrome 38.88 0.4693 <0.0001
Non-Down Syndrome 42.42 0.5285  
    
Down Syndrome with 
Alzheimer’s Disease
41.63 0.8425 0.0392
Down Syndrome without 
Alzheimer’s Disease
39.66 0.2845
Table 1
LIVER DISEASE IN DOWN SYNDROME VS. NON-DOWN SYNDROME PATIENTS
liver 
disease
no liver 
disease
Down Syndrome 12 35
Non-Down Syndrome 54 104 Chi-Square = 1.240; 
d.f.= 1; 
p=0.265
continues to be a matter of debate17, 18, 19). Another 
possibility is that patients with higher serum 
albumin levels had a greater risk of developing 
Alzheimer’s Disease, in which case the albumin level 
is most likely to be a confounder; it is difﬁcult to 
see, however, how this might relate to established 
risk factors for Alzheimer’s Disease (e4 allele of 
apolipoprotein E, vascular risk factors, head injury, 
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etc). The number of patients with Alzheimer’s 
Disease (12) was low, but the result is statistically 
signiﬁcant nonetheless. 
This study did not control for the use of anti-
epileptic drugs, which can lower serum albumin 
concentrations20, but epilepsy may not be as 
common in Down Syndrome as in many other causes 
of learning disability21; our estimate of the effect of 
Down Syndrome on serum albumin concentrations 
may therefore be an underestimate. 
It may be that there was a signiﬁcant difference in 
the prevalence of liver disease between Alzheimer’s 
Disease and non-Alzheimer’s Disease groups, which 
we failed to detect. One limitation of the study is 
the absence of histological or serological evidence 
for liver disease or viral infection. Although the 
serum alanine-aminotransferase level is the most 
important test in the detection of acute and chronic 
liver disease22, its concentration is not related to 
the severity of acute, and only weakly related to 
the severity of chronic, hepatic injury23. There is, 
however, no reason why erroneous results should 
be preferentially distributed either in the Down 
Syndrome, non-Down Syndrome, Alzheimer’s 
Disease, or non-Alzheimer’s Disease groups. 
Conﬁning our study to male subjects may have 
reduced its generalisability. It also, however, removed 
gender as a possible confounder of serum albumin 
concentration. 
Our results are consistent with the theory that Down 
Syndrome is associated with premature ageing in all 
cells24. Whether speciﬁc segments of chromosome 
21, when triplicated, are responsible for the clinical 
condition features of Down Syndrome25, or whether 
the syndrome is the result of non-speciﬁc effects of 
aneuploidy interfering with gene replication16, is still 
not clear.
A comparison study of serum albumin 
concentrations in Alzheimer’s patients with and 
without Down Syndrome, and a longitudinal study 
of serum albumin concentrations in Down Syndrome 
before and after the onset of Alzheimer’s Disease 
might each shed further light on the natural history 
of both conditions. It is unlikely that serum albumin 
level is a risk factor for Alzheimer’s Disease in Down 
Syndrome, and further work is needed to explain the 
association. We have conﬁrmed that Down Syndrome 
patients have low serum albumin concentrations and 
have provided evidence that this is not due to acute 
or chronic liver disease; we have documented the 
relation between albumin concentration and age in 
Down Syndrome and non-Down Syndrome patients; 
and we have found that, for reasons that are not yet 
clear, Down Syndrome patients with Alzheimer’s 
Disease have higher serum albumin concentrations 
than those without Alzheimer’s Disease. 
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INTRODUCTION
The number of elderly persons in the general 
population is progressively increasing worldwide 
and Ireland is no exception to this trend. According 
to the most recent data from the Republic of Ireland 
Central Statistics Ofﬁce [CSO], there were 436,001 
persons aged 65 or greater in Ireland in 2002 (total 
population of 3,917,203). Data published early this 
year (2005) from the CSO predict that the elderly 
population (aged >65 years) will double in Ireland 
between the years 1996 and 2031, increasing from 
the current rate of approximately 414,000 to around 
850,000. The average life expectancy in the Republic 
of Ireland has increased from 57.9 years for someone 
born in 1926 to 76 years for someone born in 2002 
(78.7 years for females and 73 years for males). For 
someone aged 65, life expectancy for males has 
increased from 12.8 years in 1926 to 15.4 years in 
2002. In females the ﬁgures are even more signiﬁcant 
with average life expectancy at 65 having increased 
from 13.4 years in 1926 to 18.7 years in 2002.1
Taking this in conjunction with the fact that end 
stage renal disease (ESRD) increases with advancing 
age, the need for renal replacement therapy in the 
elderly has expanded dramatically. The number 
of dialysis patients older than 65 years has more 
than doubled within the past 10 years in the United 
States.2 In Europe, patients older than 60 years 
now account for more than 50% of the population 
requiring renal replacement therapy. In Italy and 
in France, 35% of dialysis patients are now over 70 
years.3 Haemodialysis is the most commonly used 
modality in these patients but transplantation is 
now increasingly considered as a management 
option in this growing elderly population. Although 
many elderly patients on dialysis are frail, a 
consistent number are in good physical health 
and do not have associated major co-morbid 
conditions that would be a contraindication to renal 
transplantation.
In this retrospective study, we report a single-centre 
long-term follow-up of kidney transplantation in 
patients aged 65 years and older. The purpose of 
this study was to evaluate patient and graft survival 
in renal transplants cases performed at Beaumont 
Hospital between the years of 1986 and 2001 and 
identify factors, which inﬂuenced this.
Renal transplantation in the elderly - the 
Irish experience
ABSTRACT 
Background  The aim of this paper was to evaluate patient and kidney graft survival rates 
in renal transplant recipients and compare the outcomes between the different 
patient age groups. 
Methods  A retrospective review of all adult renal transplants performed at Beaumont 
Hospital between the years 1986-2001 was carried out. Patients were deﬁned as  
‘elderly’ if they were 65 years of age or older and  ‘younger’ if less than 65 years 
at the time of transplantation.  Patient and transplant graft survival rates were 
analysed for each age group.
Results  Data were analysed on 1462 ‘younger’ patients and 105  ‘elderly’ renal transplant 
recipients. Estimated patient survival at 1, 5 and 10 years were 96%, 87% and 74% 
in the younger patient group compared to 85%, 59% and 33% in the elderly group. 
The adjusted graft survival rates (adjusted for death due to other causes and with 
a functioning graft in situ) for the younger group were 89%, 77% and 64% at one, 
ﬁve and ten years respectively, while for the elderly group, adjusted one, ﬁve and ten 
year survival rates were 89%, 83% and 70% respectively.
Conclusions  Although the elderly have a shorter life expectancy than the younger 
population they do beneﬁt from renal transplantation similar to the younger 
recipients.
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MATERIALS/METHODS
We conducted a retrospective review of all adult 
kidney transplant recipients who attended 
Beaumont Hospital during the study period from 
January 1986 through to December 2001 (or at 
Jervis Street Hospital prior to its relocation to the 
current site at Beaumont). Beaumont Hospital is 
the only centre performing renal transplantation in 
the Republic of Ireland. The Irish Renal Transplant 
Registry receives annual follow-up data on all renal 
transplant patients. A dedicated Renal Transplant 
Database has been in operation since the year 
2000 and information attained since this time is 
collected and stored prospectively. Data attained 
prior to 2000 were attained retrospectively. As 
part of a cardiological assessment prior to renal 
transplantation all patients require a minimum of 
electrocardiogram, chest x-ray and cardiac exercise 
stress test. The decision to perform coronary 
angiography is guided by these investigations, 
although all diabetics and other high-risk candidates 
undergo routine coronary angiography. Any 
signiﬁcant correctable cardiac lesions must be 
treated prior to placing a potential candidate on the 
transplant waiting list. Patients are then admitted 
to the transplant pool once work-up is complete and 
the patient has been deemed medically ﬁt for the 
procedure. Criteria used for the selection of suitable 
recipients were the number of HLA mismatches 
and length of time waiting on the transplant pool. 
Consideration is also given to the ‘age-matching’ of 
donor kidneys to the renal transplant recipient. The 
vast majority of transplants performed at our centre 
are cadaveric grafts.
We have never had any speciﬁed age limit criteria 
for offering renal transplantation in our institution. 
The decision on a patient’s suitability is made on 
an individualised basis between the Nephrologist, 
Transplant Surgeon, each individual patient and 
their families. Standard immunosuppression of all 
renal transplants from 1986 to 1994 consisted of 
Cyclosporin A, Azathioprine and Corticosteroids. 
During 1992 FK506 (Tacrolimus) was introduced for 
the treatment of high immunological risk patients 
and in 1996 Mycophenolate Mofetil was introduced. 
In general all patients at our institution receive a 
triple therapy immunosuppression regime consisting 
of Cyclosporin (or Tacrolimus), azathioprine (or 
mycophenolate mofetil) and oral corticosteriods.
Kaplan Meier methods were used to determine 
survival estimates and Log rank tests compared 
survivor functions between the two groups. Non-
parametric (Wilcoxon) and Pearson chi squared tests 
were used for comparing demographic variables 
between the different groups. Results were deemed 
signiﬁcant for p values <0.05. Stata (Version 8, Texas) 
was used in all of the statistical analysis.
RESULTS
During the 16-year period from 1986 to 2001 a total 
of 1762 kidney transplant operations representing 
1582 adult recipients were performed at Beaumont 
Hospital. All but nine of these transplants were 
cadaveric grafts. Data were available for 1567 patients 
(99%). We grouped our patients into those under 65 
years of age (1462 patients – the  ‘younger ‘patient 
group) and those 65 years old or greater (105 patients 
– the  ‘elderly’ group). [The 15 patients on whom 
data was not available were all in the under 65 years 
group.] The median age of a transplant recipient in 
the younger group was 41 years as compared with 
67.5 years in the elderly patient group. Data from the 
Irish Renal Transplant Registry show the median age 
of transplant recipients in the 1960’s was 36 years. 
In 2002 this was 46 years. In the past decade this 
elderly population has grown to make up 8% of the 
total transplant service.
The ratio of male to female transplant recipients 
was signiﬁcantly different between the two groups 
with 1.8 male to 1 female recipients in the younger 
group compared to 3 males for every female in 
the elderly group. Donor age was also signiﬁcantly 
different for the two age groups (Table 1). The cause 
of the ESRD was documented as determined by 
the attending physician. The glomerulonephritides 
and genetic diseases (e.g. Adult Polycystic Kidney 
Disease, Alport’s) were more common in the younger 
population while hypertension and renovascular 
disease were more prevalent in the elderly (Table 2).
Patient survival 
The one-, ﬁve- and ten-year patient survival rate for 
the younger group was 96%, 87% and 74% versus 
87%, 60% and 34% in the older group. Overall survival 
rates between the two groups were signiﬁcantly 
different (p<0.001). Median patient survival following 
transplantation in the younger group was estimated 
at 22.0 years compared to 7.2 years in the elderly 
group. Of the older patient group (105 patients), 37 
patients were followed-up beyond ﬁve years and 13 
were followed beyond 10 years. Unfortunately we do 
not have adequate data available to compare these 
elderly patients who did receive a transplant with 
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those who were also placed on the renal transplant 
waiting list but did not get a kidney. We can however 
compare them with those patients who were on the 
chronic dialysis programme at Beaumont Hospital 
during a similar time period. A recent single centre 
study from Beaumont Hospital (from 1989 – 2003) 
showed the median patient survival for those 
patients commencing dialysis aged > 65 years was 
2.25 years but this group included some very frail 
and elderly patients. Further analysis on the patients 
starting on chronic dialysis aged 65 – 75 years 
showed a median patient survival rate of 2.57 years 
(unpublished data).
During our study period 42 of our 105 elderly 
transplant patients died. Death occurred suddenly, 
while outside the hospital setting in 9 of these 
patients. Of these 42 patients who died, cause 
of death was due to cardiovascular (including 
peripheral and cerebrovascular) complications in 
27 patients (64%) and sepsis in 10 (22%), which was 
predominantly respiratory. One patient died from 
a primary malignancy. During our study period a 
total of 134 deaths were recorded in the less than 65 
years old age group. The commonest cause of death 
in this age group was cardiovascular in 66 (49%), 
malignancy in 33 cases (25%) and sepsis in 22 (16%).
Graft survival
The one-, ﬁve- and ten-year graft survival rate for 
the younger group was 86%, 68% and 46% versus 
80%, 51% and 24% in the older group. Again these 
ﬁgures show signiﬁcant differences between the 
two groups (p<0.001). The median graft survival 
following transplantation in the younger group was 
9.4 years compared to 5.3 years in the elderly group. 
However, when graft outcome was censored for 
death with a functioning graft it showed that most 
of the elderly patients died with a functioning renal 
transplant in situ and died in fact from other causes. 
The adjusted graft survival rates for the younger 
group were 89%, 77% and 64% at one, ﬁve and ten 
years respectively, while for the elderly group, one-, 
ﬁve- and ten-year survival rates were 89%, 83% and 
70% respectively. The difference in survival estimates 
was not signiﬁcant at the 5% level, (p=0.4448) and a 
graph illustrates similar outcomes between the two 
groups (Figure 2). 
DISCUSSION
Our results clearly demonstrate that renal 
transplantation is a feasible option and should be 
considered in the elderly ESRD patient. The median 
graft survival time in elderly patients was 5.3 years 
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Table 1
PATIENT DEMOGRAPHICS
VARIABLE
ADULT TX 
RECIPIENT 
AGE < 65 YEARS
ADULT TX 
RECIPIENTS 
AGE > 65 YEARS
P VALUE
Median age at 
transplant
41 67.5 – 
Sex M/F ratio 1006/561 79/26 0.023
HD/PD ratio 1105/444 77/29 0.756
Median donor age 35 45 <0.001 
HLA kidneys good 
match/other
389/1055 26/73 0.883
PRA mean (%) 15.68 9.24 0.414
Table 2
CAUSE OF END STAGE RENAL DISEASE
CAUSE OF ESRD 
TX RECIPIENTS 
AGE < 65 YEARS, %
TX RECIPIENTS
AGE > 65 YEARS, %
Chronic GN (%) 40.0 21.0
Hypertension (%) 5.5 25.5
Chronic PN (%) 16 8.5
Inherited (%) 13.5 10.0
Diabetes (%) 7.0 5.5
Miscellaneous (%) 10.0 10.0
Obstructive (%) 1.0 6.0
Deposition (%) 1.0 3.0
Unknown (%) 6.0 10.5
thereby offering more than half of this patient 
group at least ﬁve years of dialysis-independent 
life. Furthermore when our ﬁgures were adjusted 
for death with a functioning graft we found that 
graft survival rates were similar between the two 
age groups. Although the elderly patients do have a 
shorter life expectancy, they do beneﬁt from renal 
transplantation similar to younger renal transplant 
recipients.
Prior to the introduction of calcineurin inhibitors 
(1983 in Ireland), renal transplantation was not 
ABBREVIATIONS —  TX: transplant; HD: haemodialysis; PD: peritoneal dialysis; 
GN: glomerulonephritis; PN: pyelonephritis; HLA: human lymphocyte 
antigen; PRA: panel reactive antibody.
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advocated as a treatment of end stage renal failure 
for patients older than 60 years because of poor 
patient and graft survival rates. Studies performed in 
this era showed no signiﬁcant difference in survival 
between elderly patients on regular dialysis and 
patients who underwent renal transplantation.4,5 
Recently, the US Renal Data System demonstrated 
that in patients over 65 years, renal transplantation 
reduced the risk of death more than threefold when 
compared with dialysis.6 This is supported by a 
Canadian study by Schaubel et al that found the 
5-year survival for patients aged greater than 60 
years was 80% for transplanted patients and 50% 
for those that remained on dialysis.7 However, it is 
incorrect to directly compare those elderly patients 
who receive a kidney transplant to those who remain 
on chronic dialysis. It must be considered that the 
patients that are put forward for transplantation are 
generally in better health, deemed more ‘medically 
ﬁt’ and have less co-morbid illnesses than those 
patients who continue on dialysis. 
Bonal et al, in a Spanish study demonstrated that the 
initial 1-year survival was actually better for dialysis 
patients, however, after ﬁve years the survival was 
86% for transplant patients versus 77% for dialysis 
patients.8 A large Italian study by Segoloni et al found 
the 5-year survival for patients > 55 years was 85% 
in transplanted patients versus 72% for patients on 
dialysis3. Other researchers have found that graft 
survival rates are not signiﬁcantly different in the 
older age group.9 Analysis of UNOS data showed that 
the 5-year graft survival was similar in transplant 
recipients aged above 60 years and in those aged 0-
60 years. However, graft survival rates then declined 
in the elderly patients after the 5th year because of 
their higher rate of patient death. The functional-
graft survival was actually slightly better for patients 
> 60 years, because of the lower number of grafts 
lost due to rejection in this group.10 Comparing this 
study to our own experience we also demonstrated 
that adjusted graft survival rates were broadly 
similar between the two groups and that the graft 
loss in the elderly group was mainly due to patient 
death from other causes. The difference in graft 
survival rates between the two reports may in part 
be explained by the fact that the age deﬁnition of 
the ‘elderly group’ was also different as they deﬁned 
the elderly patient group as greater than 60 years 
(compared to 65 years in our study).
Due to the improving results of transplantation, 
the impact of the recipient’s age has become 
less relevant and therefore, age per se no 
longer constitutes a contraindication to renal 
transplantation. The Irish results reﬂect what 
is happening worldwide and we too are seeing 
an increasing number of patients over 65 years 
considered for transplantation. Of all kidney 
transplants performed at our institution between 
1986 and 2001, 5.2% were in recipients at least 65 
years old at the time of transplant. There has been 
a gradual rise in the number of elderly patients 
receiving renal transplants over the study period. In 
Figure 1 — GRAPH OF TRANSPLANT RECIPIENT SURVIVAL BY AGE GROUP
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Figure 2 — GRAPH OF TRANSPLANT GRAFT SURVIVAL RATES CENSORED FOR DEATH 
WITH A FUNCTIONING GRAFT BY AGE GROUP
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2001 the elderly accounted for 9.2% of the total renal 
transplant workload at our institution. The issue 
of offering a kidney to an elderly patient remains 
controversial when we consider the number of 
younger people who remain on the renal transplant 
waiting lists. However, as consideration is also given 
to  ‘age-matching’ in the allocation of potential 
donors and recipients it is generally the situation 
that a younger donor kidney is likely to be offered to 
a younger recipient and older donor kidneys to an 
elderly candidate. In this study the mean donor age 
was signiﬁcantly different between the two patient 
groups, 35 years in the younger patient group versus 
45 years in the elderly patient group (Table 1).
Recently published work by Briggs et al in Scotland 
has shown that the survival of patients who have 
undergone renal transplantation has improved 
considerably over the past two decades11. This is due 
mainly to better immunosuppressive regimes but 
also to a combination of better surgical techniques, 
safer anaesthetic practices, and lesser infective 
deaths. Cardiovascular disease, infectious conditions 
and malignancy now account for most of the deaths 
in the elderly population.11, 12
Data from our institution show unequivocally 
that for those patients in whom surgical 
contraindications are absent, renal transplantation 
is a feasible option for the older ESRD patient. In our 
experience those patients who are deemed ﬁt for 
transplant and do actually receive a kidney do better 
than their age-matched counterparts who remain on 
dialysis. We propose an integrated approach to the 
management of renal failure in elderly patients and 
concur with previous studies that age 65 years and 
greater should not bias the clinician away from the 
beneﬁts of renal transplantation.
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INTRODUCTION
Injecting drug users (IDUs) are at high risk of 
acquiring hepatitis C (HCV),1 hepatitis B (HBV)2 and 
human immunodeﬁciency virus (HIV)3 infections. 
Harm reduction interventions have been advocated 
in order to prevent the spread of bloodborne virus 
infections.4 Since 1992, the Irish Government has 
pursued a policy of harm reduction by providing 
methadone maintenance, needle exchange 
programmes and education through outreach 
programmes.5 
Despite the increasing availability of harm reduction 
interventions, recent studies have estimated that 
between 52% and 80% of opiate users in Dublin 
are infected with HCV,6-9 with the incidence of HCV 
in this population estimated to be higher than 
previously reported.10 In addition, between 19% and 
28% of opiate users are positive for anti hepatitis B 
core antibody (anti-HBc), while between 1% and 17% 
are infected with HIV.6-8
The World Health Organisation recommends 
universal childhood immunisation against HBV.11 
The recently published immunisation guidelines for 
Ireland recommend that HBV vaccine be given to 
those at risk of infection, as three doses at intervals 
of zero, one and six months and in cases at high 
risk of infection, at intervals of zero, one and three 
months with a booster dose at 12 months.12 
While it has been suggested that specialist addiction 
treatment centres are an effective setting in which 
to deliver targeted immunisation programmes for 
opiate users,13 a recent study in Dublin found only 
one-third of clients attending such centres had 
Bloodborne virus infections among drug users 
in Ireland: a retrospective cross-sectional 
survey of screening, prevalence, incidence and 
hepatitis B immunisation uptake
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evidence of immunity to HBV or evidence of having 
started an immunisation programme.7 Following the 
low uptake of HBV immunisation highlighted in this 
report, recommendations were devised regarding 
a vaccination protocol and were subsequently 
implemented within the addiction services. Low 
rates of HBV immunisation uptake have also been 
reported elsewhere.14 
It has been suggested that harm reduction 
interventions, in particular methadone maintenance, 
may not be effective in preventing the transmission 
of bloodborne viruses.15 16 A recent study in Dublin 
reported continued high risk activity among drug 
users despite an increase in availability of harm 
reduction interventions.17 
As a result, continued monitoring of care provided 
to drug users at risk of blood borne virus infections 
and epidemiological surveillance of blood borne virus 
infections among this population is important. The 
aims of this study, therefore, are to:
• document screening for bloodborne virus 
infections; 
• determine the prevalence and incidence of 
these infections;
• describe current care processes regarding 
HBV immunisation.
METHODS
Setting
The Eastern Regional Health Authority (ERHA) area 
(with a catchment population of over 1.3 million 
people) is Ireland’s largest health region.18 It is 
estimated that at least 13000 people in the ERHA 
area are current or former, opiate users.19 In 1998, 
over 5000 people (85% of the national total) were 
receiving methadone treatment in the region.20 
Methadone treatment services in the area are 
provided by: specialist addiction treatment centres, 
community based projects (satellite clinics) and 
General Practitioners (GPs).
Three local area health boards (Northern, South 
Western and East Coast area health boards) are 
responsible for the planning and delivery of health 
and social services in the ERHA. The area covered 
by the South Western Area Health Board (SWAHB) 
includes south-west County Dublin, County Kildare 
and the western part of County Wicklow. Of the six 
postal districts in the ERHA region with the highest 
prevalence of illicit opiate use, three are located in 
the SWAHB area.19
A total of 21 clinics provide methadone treatment 
in the SWAHB area. These clinics range from large 
centres staffed by a fulltime multidisciplinary team 
to smaller satellite clinics based in community 
centres or in local health centres. The larger clinics 
dispense methadone while the smaller clinics 
provide methadone prescriptions, which are ﬁlled in 
community pharmacies.
Subjects
A total of 1,459 current or former heroin users were 
attending specialist addiction treatment centres in 
the South Western Area Health Board in December 
2001. A one-in-four consecutive sample was selected 
from a listing of clients attending treatment (held by 
the Department of Health and Children on a Central 
Treatment List) at the time. 
Data collection
A member of the research team reviewed the 
medical records of the sample population. 
Anonymised data regarding demography, drug using 
history, blood borne virus status and blood borne 
virus related care was recorded. Data regarding 
bloodborne viruses was taken from laboratory results 
or documentation from outside agencies that were 
present in individual client records. 
Following the sampling process six clients were 
excluded from the study owing to the absence of 
information regarding bloodborne viral status and 
related care in their medical records. 
The survey was carried out over a six-week period 
between December 2001 and January 2002.
Data analysis
Data were analysed using Statistical Packages for 
the Social Sciences (SPSS) version 10.0. Analytical 
techniques included Pearson’s chi squared test to 
determine the signiﬁcance of associations between 
categorical variables (HCV or HIV serostatus and 
age). Student’s t-test was used to compare means 
between groups. 
The incidence of infections was measured using the 
persons year method, and is expressed as the number 
of seroconversions per hundred person years (HPY) at 
risk, with 95% conﬁdence intervals (CI).16 21 22 The date 
of the ﬁrst negative test represented the starting 
point for all patients when calculating their person 
years at risk. The endpoint was the date of the last 
negative test for those who remained seronegative.
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The estimated date of seroconversion was used as 
the endpoint for those who seroconverted and this 
was calculated by ﬁnding the midpoint between 
their negative and positive tests.
Viral markers
Testing for hepatitis C antibodies (anti-HCV) prior 
to 1993 in the Dublin area was with a second 
generation enzyme linked immunoadsorbent assays 
(EIA) and with a third generation EIA thereafter with 
positive assays conﬁrmed by radioimmunoblot (RIBA) 
assay. Initial screening for HIV antibodies (anti-HIV) 
involves two EIAs, with positive assays conﬁrmed by 
Western Blot assay. The screening test for both HBV 
surface antigen (HBsAg) and core antibody (anti-HBc) 
is an EIA. 
RESULTS
Population characteristics
Of the 358 clients surveyed, 214 (60%) were male, the 
median age was 26 years (range 16-51) and the median 
length of time attending methadone treatment 
services was 24 months (range 1-221 months). 
Screening for bloodborne viruses
A total of 316 (88%) had evidence of testing for HCV, 
244 (68%) had evidence of testing for hepatitis B 
core antibody, 299 (84%) had evidence of testing 
for hepatitis B surface antigen and 307 (86%) had 
evidence of testing for HIV. The majority of clients 
had not been tested within the previous 12 months.
Of those who had been tested for exposure to 
bloodborne viruses, 207 (66%) tested positive for 
the presence of anti-HCV antibody, 42 (17%) tested 
positive for the presence of HBV core antibody, six 
(2%) tested positive for the presence of HBV surface 
antigen and 33 (11%) tested positive for the presence 
of anti-HIV antibody.  
Clients aged 25 years or over were signiﬁcantly more 
likely to test positive for the presence of anti-HCV 
antibody (75% compared to 47%, p<0.001), but not for 
anti-HBc antibody (19% compared to 13%, p=0.211), 
HBsAg (3% compared to 1%, p=0.309) or HIV (11% 
compared to 9%, p=0.468).
One hundred and twenty tested negative for the 
presence of anti-HCV antibody on initial testing. Of 
these, 27(23%) had at least one follow-up test, with 
11 testing positive for the presence of anti-HCV at 
follow-up, giving an incidence of 24.5 (95% CI=12.2-
43.8) per hundred person years at risk.
Two hundred and ﬁve tested negative for anti-HBc 
antibody on initial testing. Of these, 18 (9%) had at 
least one follow-up test, with three testing positive 
for the presence of anti-HBc antibody at follow-up, 
giving an incidence of 9.0 (95% CI=1.9-26.3) per 
hundred person years at risk. 
Two hundred and seventy eight tested negative for 
the presence of anti-HIV antibody on initial testing. 
Of these, 59 (21%) had at least one follow-up test, 
with four testing positive for the presence of anti-HIV 
antibody, giving an incidence of 3.4 (95%CI=0.9-8.7) 
per hundred person years at risk. 
The median intervals from testing negative to 
testing positive for anti-HCV antibody, anti-HBV core 
antibody and anti-HIV antibody were: 40 months 
(range 16-44), 34 months (range 19-44) and 26 
months (range16-44) respectively.
The length of time a client was in treatment was 
associated with having a second test for anti-HCV 
antibody (p=<0.001), anti-HBc antibody (p=<0.001) 
and anti-HIV antibody (p=<0.001). Age was not 
signiﬁcantly associated with having a repeat test for 
any of the three bloodborne viruses. 
HBV immunisation 
While 81% of clients in whom HBV immunisation 
was indicated had received at least one vaccine, 
with 69% of these completing the recommended 
schedule, 15% had never received a vaccine while 
in treatment and 4% had a documented refusal 
(see Figure 1). The median interval from entering 
treatment to receiving a ﬁrst vaccine against HBV 
was 6 months (range 1-24 months). For those 
clients who entered treatment within the last 24 
months, this interval was signiﬁcantly shorter (three 
compared to 15 months, p<0.001). 
Of the 177 clients who had received a completed 
course of HBV immunisation, 134 (76%) were 
tested for anti-HBs antibody (see Figure 3 for the 
distribution of anti-HBs titres). Twenty (15%) of these 
were found to have an anti-HBs antibody level of less 
than 10miu/ml, of whom 15 had been revaccinated 
(see Figure 2). 
DISCUSSION
Methodological considerations
It is with some caution that these ﬁndings can be 
extrapolated to all drug users in treatment in Ireland. 
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This study presents data on a cross-section of clients 
receiving methadone treatment in one of Dublin’s 
three health board areas in late 2001 and early 2002. 
The sample is older (36% compared to 58% aged 
under 25) and contains a smaller proportion of males 
(60% compared to 70%) than the most recently 
published data on the total population attending 
addiction treatment services in Ireland.20 In addition, 
as data were extracted from clinical records, it is 
possible our ﬁndings may not accurately report the 
true process of care delivered. 
Screening
The proportion of patients without documented 
evidence of testing was 12% for HCV, 32% for anti-
HBc, 16% for HBsAg and 14% for HIV. It is difﬁcult 
therefore to accurately determine prevalence of 
bloodborne virus infections in the study sample. Of 
greater importance, however, is the fact that the 
health status of those who have not been tested is 
unknown. 
A review of bloodborne virus care among clients 
attending addiction treatment centres in the same 
area was conducted using a similar methodology in 
1997.7 As only 60% of clients had been screened for at 
least one bloodborne virus infection, a standardised 
written protocol for bloodborne virus screening was 
subsequently introduced to the service. Our ﬁndings 
indicate that uptake of screening for bloodborne 
viruses has increased since the introduction of this 
protocol. 
Problems in ensuring complete uptake of testing for 
these viruses has been reported among drug users in 
other settings.23 24 To date, few data exist on reasons 
why such difﬁculty is experienced in ensuring 
adequate screening for bloodborne viruses among 
this population. Previous work in the Dublin area 
has highlighted a deﬁciency in knowledge regarding 
HCV among drug users, particularly where primary 
prevention is concerned.25 As well as incorporating 
primary prevention into education programmes 
aimed at drug users, it is possible healthcare 
professionals working with drug users also need to 
discuss the importance of secondary prevention, 
speciﬁcally the importance of screening for previous 
exposure to any of these viruses. 
Prevalence
It is encouraging to ﬁnd the prevalence of anti-HCV 
antibody (66%), anti-HBc antibody (17%), HBsAg 
(2%) and anti-HIV (11%) antibody to be lower than 
observed in a similar study in the same area four 
years ago.7 It is possible these ﬁndings may be in part 
explained by the recent increase in availability of 
harm reduction facilities in the Dublin area. 9
Age or length of injecting career are associated with 
testing positive for HCV, HBV or HIV.6 26 While the 
ﬁnding that younger drug users have a signiﬁcantly 
lower prevalence of HCV infection is reassuring, the 
similar prevalence of HIV infection among those 
aged under 25 is a source of some concern. Another 
recent study examining the epidemiology of HIV 
infection among IDUs in the Dublin area reported an 
increase in the number of new cases of HIV among 
young IDUs.27 
The observed bloodborne virus prevalence is 
however, higher than reported in a large cross-
sectional survey of new clients presenting to a 
specialist addiction clinic in Dublin between 1992 
and 1997.6 This difference is likely to be explained by 
the fact that our sample had been in treatment for 
longer and was older (36% compared to 73% aged 
under 25). 
The prevalence and incidence rates of the 
bloodborne viruses reported in this study may be an 
under-representation of the rates among IDUs as 
the study sample included both parental and non-
parental heroin users.
Incidence
The observed incidence of HCV infection (24.5 per 
hundred person years) provides further evidence 
that injecting drug users attending treatment have 
a high incidence of HCV infection.16 28 The observed 
incidence of HCV among the sample reported in 
this paper is considerably lower than that reported 
recently among a cohort attending an addiction 
treatment centre in Dublin (66 per hundred person 
years).10 This ﬁnding may be explained by the older 
age and longer contact with treatment services 
of the cohort reported in the sample described in 
this paper, and indeed may indicate the beneﬁt of 
methadone maintenance treatment. 
However, the observed incidence of HIV infection 
(3.4 per hundred person years) is considerably higher 
than a number of recently reported incidence ﬁgures 
among injecting drug users in environments in 
which harm reduction strategies would be similar to 
those employed in Dublin.10 16 28 These are worrying 
ﬁnding for service planners in our area, as it perhaps 
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indicates that current harm reduction strategies and 
localised testing protocols, may not be effective in 
controlling the spread of HIV infection among this 
population, as has been previously suggested.29 
The majority of clients tested for bloodborne virus 
infections in this sample had not been tested in 
the past year. Furthermore, a small proportion of 
those who tested negative for bloodborne viruses on 
initial testing had subsequent screening performed. 
The high incidence of HIV and HCV, allied to the 
continued high risk activity that has been reported 
among drug users in Dublin despite increased 
availability of harm reduction interventions,17 
highlights a clear need for a standardised protocol 
for follow-up testing of drug users.
We propose the introduction of a standardised risk 
assessment model that would be performed twelve 
months following a negative test. This will enable 
clients to be assessed for risk factors associated 
with the acquisition of the bloodborne viruses and 
for those who have put themselves at risk to be 
subsequently retested. 
HBV immunisation
Immunisation against HBV is recommended for all 
injecting drug users. However there are a number 
of difﬁ culties inherent in the process of conferring 
adequate immunity to HBV among drug users. 
Uptake of targeted or opportunistic immunisation 
programmes is often poor.7 24 In addition, drug users 
are less likely to mount a protective antibody response 
to completed immunisation programmes.30 31
Among the sample studied here, 81% had 
commenced a course of vaccinations against HBV. 
While the uptake is not as high as recently reported 
in addiction treatment centres in Italy,31 it compares 
quite favourably with uptake rates reported in earlier 
studies from Dublin.7 This may be due the recent 
introduction of guidelines for HBV immunisation 
in addiction treatment services in the area,32 or 
the regular sustained contact clients have with a 
multidisciplinary team of healthcare professionals in 
addiction treatment services in the area.
Fifteen per cent of the sample who had completed 
a course of vaccinations and had been tested for 
anti-HBs were found to have an antibody titre of less 
than 10 miu/ml, thereby supporting the evidence 
that injecting drug users are less likely to mount an 
adequate immune response to currently available 
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Figure 1. — PROCESS OF IMMUNISATION AGAINST HBV
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Figure 2. — IMMUNE RESPONSE TO COMPLETED HBV IMMUNISATION PROGRAMME 
AMONG STUDY SAMPLE.
HBV vaccines.30 31 Checking for immunity to HBV and 
if necessary, revaccinating, should be considered an 
essential part of any HBV immunisation guidelines, 
therefore. 
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CONCLUSIONS
This study reports encouraging ﬁndings regarding 
uptake of testing for bloodborne viruses and an 
improvement in uptake of immunisation against 
HBV. The introduction of immunisation and 
screening protocols appear to have facilitated these 
improvements. 
The ﬁndings regarding HIV incidence and HIV 
prevalence among younger drug users are a source of 
some concern. Levels of repeat testing for bloodborne 
viruses are also concerning. There was no evidence of 
a consistent policy regarding repeat testing following 
an initial negative test and the introduction of such a 
policy within addiction services is required.
Given the prevalence and incidence ﬁgures of HCV, 
HBV and HIV in Dublin we can conclude that the 
rate of risk behaviour among IDUs remains high. 
While existing harm reduction measures have had 
an important role in the response to the medical 
and social problems resulting from illicit drug use, it 
appears their availability may need to be expanded. 
Speciﬁcally the interception of young users, new 
onset users and those progressing to injecting is 
necessary if the spread of HCV, HBV and HIV is to be 
slowed or halted. In addition, a stronger emphasis 
needs to be placed on educating drug users to enable 
the behavioural changes that are necessary to halt 
transmission of the bloodborne viruses.
It has been suggested that “a rejuvenated and 
multidisciplinary approach emphasising both 
sexual and needle sharing risk practices” could be 
important in preventing HIV transmission.27 It has 
also been suggested that a more sophisticated and 
individualised approach to harm reduction may 
be necessary.17 Based on the ﬁndings presented in 
this paper, policy-makers may need to consider a 
reassessment of current strategies with a view to 
further expansion and the adoption of alternative 
educational strategies. 
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HEALTH-RELATED QUALITY OF LIFE DURING FOUR-LAYER COMPRESSION BANDAGING FOR VENOUS ULCER DISEASE: 
A RANDOMISED CONTROLLED TRIAL
INTRODUCTION
Leg ulcers are a common and debilitating problem 
with a prevalence in Ireland of 0.12% overall, 
increasing to 1.03% in patients over 70 years of 
age.1-3 Eighty-one per cent of leg ulcers are venous 
in origin, resulting from venous hypertension.4 The 
application of graduated compression bandaging is 
the most widely recognised treatment for venous 
leg ulcers. Compression bandaging reverses venous 
hypertension promoting venous return, allowing 
the ulcer to heal,5,6 50-70% of ulcers heal at 12 weeks 
with this treatment.4,6 Venous leg ulceration is a 
chronic condition which can result in pain, limit 
mobility, alter body image and lower self-esteem, 
all of which negatively impact on patients quality 
of life.8 Therefore, when choosing treatment for a 
patient with venous ulceration it is imperative that 
treatment not only accelerates healing but also 
improves quality of life.
Many studies have examined the effectiveness 
of various treatments on ulcer healing but few 
randomised controlled trials include data on quality 
of life, which assess the impact chronic leg ulcers 
have on patients’ day-to-day lives. 9 This study aimed 
to compare four-layered compression bandaging to 
other treatments available in a community setting 
for treating venous leg ulcers and establish what 
impact this treatment had on patients’ health-
related quality of life. 
PATIENTS AND METHODS 
Public Health Nurses (PHN), Practice Nurses, and 
General Practitioners (GP) referred patients from the 
community with a suspected venous ulcer. These 
patients received written information about the 
study and were invited to attend for assessment. 
Assessment was carried out at the Mid-Western 
Regional Hospital, at local health centres, or at 
patients’ homes. Patients were included in the trial 
if they had a venous leg ulcer and were not being 
treated with 4LB. A venous ulcer was deﬁned when 
there was clinical evidence of venous disease, the 
resting ankle brachial pressure index was ≥0.9, and 
no other cause was identiﬁed. Patients meeting the 
inclusion criteria were invited to enrol in the trial and 
Health-related quality of life during four-layer 
compression bandaging for venous ulcer 
disease: a randomised controlled trial
ABSTRACT 
Background  Venous leg ulceration is a chronic debilitating condition which negatively 
impacts on patients’ quality of life. Despite the application of gold standard 
treatment a number of patients suffer from ‘slow to heal’ ulcers, which can require 
treatment for years. 
Aims The aim of this study was to compare the effects of four-layer compression 
bandaging (4LB) for treating venous leg ulcers with other available treatments on 
health-related quality of life during treatment.
Methods  In this pragmatic trial, 200 patients with venous leg ulceration were 
randomised either to 4LB (intervention group; n=100) or to continue their usual 
system of care (control group; n=100). Analysis was by intention to treat; quality of 
life measurements were taken at randomisation and after six weeks of treatment.
Results  4LB provided greater quality of life beneﬁts than the control group particularly in 
the area of physical activity and social functioning.
Conclusion  Due to the long-term nature of treatment for many of these patients, the 
effects on quality of life should be considered when prescribing treatment. This 
study has shown that 4LB signiﬁcantly improves the quality of life of patients 
during treatment for venous leg ulceration.
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written consent obtained. The trial was approved by 
the Research Ethics Committee at the Mid-Western 
Regional Hospital. 
In this prospective randomised controlled trial, 
patients were randomised to 4LB (intervention 
group) or to continue with their usual care 
(control group). Before the study began, a random 
‘intervention’/‘control’ list was generated for 200 
patients by computer, and the results entered 
sequentially into sealed numbered envelopes. These 
envelopes were assigned to consecutive patients 
once consent was obtained. Information recorded 
at the recruitment phase included the age and sex 
of the patient, the duration of the ulcer, and any 
history of deep vein thrombosis (DVT), diabetes or 
rheumatoid arthritis. The ulcerated area was also 
measured and photographed. 
Quality of life assessment was carried out at 
recruitment, with each patient completing quality of 
life assessment questionnaires. The disease speciﬁc 
quality of life instrument for chronic lower limb 
venous insufﬁciency (CIVIQ) was used,10 as well as 
the SF-36 generic questionnaire.11 The CIVIQ is a 20 
item questionnaire designed speciﬁcally to measure 
health in patients with chronic venous disease. 
The 20 questions are divided into four domains; 
psychosocial, physical functioning, social functioning 
and pain. Lower scores from this questionnaire 
reﬂect better quality of life.11 
The SF-36, a generic questionnaire, consists of 36 
questions measuring health across eight domains; 
physical functioning, role limitation due to physical 
health, bodily pain, general health, vitality, social 
functioning, role limitation due to emotional 
problems and mental health. Responses to questions 
within a domain are combined together to give a 
score from 0-100, the higher the score the better 
health indicated.12
The aim of quality of life assessment was to detect 
differences between the health status of patients in 
the two groups during treatment. No assessment 
was made at the end of the study period. The patients 
were assessed by interview at recruitment to establish 
base line scores, and again after six weeks of assigned 
treatment, if the ulcer remained unhealed (Tables 
1 and 2). Six weeks was chosen as the mid-point 
between recruitment and probable ulcer healing.
Study outcomes were differences in patients’ health-
related quality of life status at six weeks, time to 
healing and the direct cost to the health board per leg 
healed. The results from this study related to time to 
healing and cost analysis are published elsewhere.4
During the study all patients had their leg ulcers 
dressed by their usual community nurse. This 
provided for continuity of care. Prior to this study 
all public health nurses in this region attended 
formal workshops and received individual training 
in the application of 4LB. A standard 4LB was used, 
comprising a sterile wound contact dressing, a 
natural padding bandage, a light conformable 
bandage, a light compression bandage and a ﬂexible 
cohesive bandage. This combined system provided 
sustained external compression of 40mmHg at 
the ankle. The control group received a variety of 
treatments chosen by the public health nurse and 
the GP. Treatment in the control group included an 
assortment of topical dressings, such as hydrocolloids, 
alginates, parafﬁn and iodine dressings. Various 
absorbency dressings, low-pressure bandages and 
elasticated support were also used. One patient had 
laser therapy. Five patients in the control group had 
compression applied at some stage during their 
3-month study interval. Twelve patients in the 4LB 
group were non-compliant, the main reason being 
intolerance to the high compression bandage. High 
absorbency dressings (n=11) and desloughing agents 
(n=8) were used at the discretion of the nurse in 
some patients in conjunction with 4LB.
Statistical analysis
Appropriate parametric and nonparametric 
summary statistics were calculated. The two-tailed 
Student t-test and the Mann Whitney U test were 
used, respectively to analyse differences in means 
and medians. A level of signiﬁcance of 5% was used 
for all statistical tests. The sample size of 200 was 
calculated to detect differences between the two 
groups in time to healing as this was the primary 
study outcome, this sample size was also considered 
appropriate to detect differences in quality of life. 
RESULTS
Our aim was to determine quality of life for patients 
while undergoing treatment. Baseline health scores 
pre-treatment, compared well in both groups (Tables 1 
and 2). Quality of life questionnaires were completed 
for 92.9% (79/85) and 95.8% (91/95) of patients 
remaining unhealed at six weeks in the 4LB and control 
groups, respectively. The other patients did not ﬁll out 
quality of life questionnaires as their ulcer was healed 
by week six. We chose six weeks as being the optimal 
time to measure quality of life during treatment.
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Of the questionnaires used, the CIVIQ showed the 
most discernible clinical and statistically signiﬁcant 
differences in perceived health status at six weeks, 
in preference to 4LB, most especially in the domains 
of physical activity and social functioning. There 
was a signiﬁcant improvement in physical activity 
in the 4LB group with a median improvement of 
18.7 after six weeks (31.25 vs 18.2), no difference 
was detected in the control group (p=0.006, 4LB 
vs control). In the social functioning domain both 
groups baseline analysis were identical, again the 
greatest improvement after four weeks treatment 
was seen in the 4LB group, median improvement 
of 16.7 (50 vs 33.3) in 4LB and 8.3 (50 vs 41.7) in the 
control group (p=0.001, 4LB vs control). For the 
global index domain the 4LB group experienced 
greatest improvement with a median difference 
of 10 at six weeks (32.5 vs 18.8) (p=0.006, 4LB vs 
control). In support of this the SF-36 also displayed 
greater improvements in health beneﬁts using 4LB. 
The most signiﬁcant improvement after six weeks 
treatment was again seen in the area of physical 
function, the median improvement in the 4LB group 
was 15 (55 vs 70) whereas the control group showed 
a slight deterioration of 2.5 (52.5 vs 50)(p= 0.001, 4LB 
vs control). In the role-physical domain the baseline 
results for both groups were identical; after six weeks 
the control group experienced no change but the 4LB 
group showed a median improvement of 75 (25 vs 
100)( p=0.006, 4LB vs control). 
DISCUSSION 
Patients use the following words to describe life 
with a leg ulcer; pain, loss of mobility, disturbed 
sleep, offensive smell, fear, social isolation, anger, 
depression and negative self image.13,14 Most 
clinicians would accept that leg ulceration has a 
negative impact on patients’ health-related-quality-
of-life (HRQoL) and various studies have shown 
this to be true.15-17 The ﬁrst study to use HRQoL 
as an outcome measure, for patients undergoing 
treatment for venous leg ulcers was the Riverside 
leg ulcer project.15 This study assessed the effect 
of community leg ulcer clinics and concluded 
that effective treatment resulted in an overall 
improvement in patients’ QoL, with greatest 
improvements in the areas of pain, depression 
and hostility, particularly in patients whose ulcer 
healed. Few studies have examined the effects of 
treatment within randomised controlled trials.18 
Franks et al conducted a randomised trial comparing 
the effect two types of four-layered compression 
bandage system had on patients’ QoL.19 This study 
showed no statistical difference between bandage 
systems presumably due to similar healing rates 
being achieved by both bandages. Improvement was 
directly related to ulcer healing rates with signiﬁcant 
improvements in patients whose ulcer had healed, 
concluding that effective treatment is the key to 
improving QoL.19 These studies demonstrated that 
measuring health-related quality of life offers a 
holistic approach in evaluating various treatments, 
with the treatment which offers greatest healing 
rates being more likely to improve health related 
quality of life for patients. Although the concept of 
HRQoL may be difﬁcult to measure,20 in a condition 
where the primary outcome, complete healing, may 
not be realised, QoL assessment of treatment is 
crucial.21 
In measuring HRQoL quantitatively two methods 
can be employed, generic or disease speciﬁc 
questionnaires. Generic questionnaires being general 
in nature can be used for any disease and thereby 
allow for comparisons between diseases, while 
disease speciﬁc questionnaires directly relate to the 
particular disease and show greater sensitivity to 
change than generic instruments. In this study, both 
methods have been used. The tools chosen were the 
generic Short Form 36-item Health Proﬁle (SF-36), 
and the disease speciﬁc ChronIc Venous Insufﬁciency 
Questionnaire (CIVIQ).
The ﬁndings here showed statistically signiﬁcant 
differences between the two study groups in some 
SF-36 domains. Greater differences between groups 
may have been seen if the sample size was larger. 
This may be seen as a potential weakness in this 
study as the sample size chosen was calculated to 
detect differences in time to healing, but statistically 
signiﬁcant differences were seen which indicate that 
this generic tool was successful in measuring quality 
of life changes.
The CIVIQ, being disease speciﬁc, showed 
slightly more clinical and statistically signiﬁcant 
differences in favour of 4LB. This was especially 
true in the domains of physical activity and social 
functioning. The global index also showed a 
statistically signiﬁcant improvement in favour of 
4LB. The improvements in QoL detected in favour 
of the patients treated with 4LB may be attributed 
to improved healing rates which this group 
experienced,4 indicating that quality of life is directly 
related to rates of healing. 
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Table 1.
PATIENT PERCEIVED HEALTH STATUS (SCORES) BY RANDOMISED GROUP SF-36
BASELINE
MEDIAN
(INTER-QUARTILE RANGE)
WEEK 6
MEDIAN
(INTER-QUARTILE RANGE)
DIFFERENCE IN GROUPS 
AT WEEK 6
MANN WHITNEY U TEST
SF-36
Physical 
Function 
4LB 
Control
Role-Physical 
4LB 
Control
Bodily Pain 
4LB 
Control
General Health 
4LB 
Control
Vitality 
4LB 
Control
Social Function 
4LB 
Control
Role-Emotiona 
4LB 
Control
Mental Health 
4LB 
Control
 
 
55 (35-80) 
52.5 (25-80)
 
25 (0-100) 
25 (0-100)
 
52 (42-84) 
51.5 (41-72)
 
77 (67-82) 
72 (62-82)
 
65 (55-75) 
60 (50-75)
 
75 (50-100) 
75 (50-100)
 
100 (0-100) 
100 (0-100)
 
88 (80-92) 
84 (76-88)
 
 
70 (45-85) 
50 (25-80)
 
100 (0-100) 
25 (0-100)
 
84 (61-100) 
72 (51-100)
 
77 (62-87) 
72 (62-82)
 
75 (60-80) 
60 (55-75)
 
100 (75-100) 
87.5 (62.5-100)
 
100 (100-100) 
100 (33.3-100)
 
88 (80-92) 
88 (76-92)
 
 
p=0.001
 
 
p=0.006
 
 
p=0.840
 
 
p=0.202
 
 
p=0.160
 
 
p=0.322
 
 
p=0.150
 
 
p=0.030
6 week assessment: 4LB n=79, control n=91. 
Higher SF-36 scores indicate better health status.  The converse applies to the CIVIQ
Table 2.
PATIENT PERCEIVED HEALTH STATUS (SCORES) BY RANDOMISED GROUP CIVIQ
BASELINE
MEDIAN
(INTER-QUARTILE RANGE)
WEEK 6
MEDIAN
(INTER-QUARTILE RANGE)
DIFFERENCE IN GROUPS 
AT WEEK 6
MANN WHITNEY U TEST
CIVIQ
Pain 
4LB 
Control
Physical 
4LB 
Control
Social 
4LB 
Control
Psychological 
4LB 
Control
Global 
4LB 
Control
 
43.75 (25-62.5) 
50 (31.3-62.5)
 
31.25 (12.5-50) 
37.5 (25-62.5)
 
50 (33.3-66.7) 
50 (33.3-66.7)
 
19.4 (11.1-33.3) 
22.2 (13.9-33.3)
 
32.5 (20.0-45.0) 
36.3 (22.5-48.8)
 
18.8 (6.3-37.5) 
31.3 (18.8-43.8)
 
12.5 (6.3-37.5) 
37.5 (12.5-62.5)
 
33.3 (16.7-41.7)
41.7 (25-58.3)
 
13.9 (11.1-25)
19.4 (11.1-27.8)
 
18.8 (12.5-31.3)
28.8 (18.8-43.8)
 
p=0.140 
 
p=0.006 
 
p=0.001 
 
p=0.488 
 
p=0.006
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In assessing quality of life we chose to use 
quantitative analysis, another possibility would have 
been to take a qualitative approach and carry out 
interviews with sample patients from both groups. 
For this study we felt it would be more accurate to 
assess a large number of patients quantitatively in 
order to obtain a global view of patients with venous 
leg ulceration. Future research may be carried out to 
determine whether qualitative research produces 
similar results.
CONCLUSION
Leg ulcers greatly impact on patients’ day-to-day 
lives, reducing their quality of life. The aim of venous 
leg ulcer treatment is complete healing, however as 
this may not always be attainable quality of life must 
be recognised as an important outcome measure. 
This study examined the effect of treatment on 
patients’ quality of life. The results highlighted the 
quality of life beneﬁts which 4LB provides, namely 
improved physical and social functioning, concluding 
that 4LB provides increased quality of life beneﬁts 
when compared to alternative dressing options.
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INTRODUCTION
Myeloma is a malignancy of mature B-cells (plasma 
cells) and is characterised clinically by anaemia, 
bone pain and renal impairment. The median age 
at diagnosis is 65 years and it represents 10% of 
haematological cancers in most registries.1 The 
combination of melphalan and prednisolone (MP) 
has been widely used in the treatment of myeloma, 
yielding survival of approximately three years.2 
Despite many trials of more complex chemotherapy 
regimens, meta-analysis failed to demonstrate 
that any were superior to MP in terms of OS.3 
Interest therefore focused on exploiting the known 
dose-response effect seen with melphalan. The 
UK Royal Marsden Hospital group was the ﬁrst to 
report the achievement of complete responses in a 
large proportion of those receiving higher doses.4 
The subsequent addition of autologous marrow 
and myeloid growth factor support allowed dose 
escalation to 200mg/m2.5 A seminal randomised 
trial leading to the more widespread acceptance 
of autografting in myeloma was published by the 
IFM French Myeloma Group in 1996.6 High-dose 
therapy was associated with a ﬁve-year Overall 
Survival of 52% compared to 10% in the conventional 
chemotherapy arm. The superiority of ASCT in term 
of PFS and OS has since been conﬁrmed by other 
centres.7-8 In the UK myeloma VII trial, ASCT increased 
median survival by almost one year (54.1 months vs. 
42.3 months).8
Transplantation techniques continue to be reﬁned. 
The choice of conditioning regimen, methods of 
processing of the stem cell product and aspects of 
supportive care have evolved over the last decade.9-10 
Novel agents have also been introduced in the 
treatment of relapsed disease post-autograft. We 
present data on 60 patients with MM who have 
undergone HDT with ASCT at the National Bone 
Marrow Transplant centre between 1997 and 2003. 
Patient demographics, pre-transplant characteristics, 
engraftment data, post-autograft treatment details 
and survival rates are provided. 
METHODS
Patients 
This study was approved by the hospital research 
ethics committee. Sixty patients with myeloma 
received HDT with ASCT at the National Bone 
Marrow Transplant centre at St. James’s Hospital 
between January 1997 and December 2003. Clinical 
details are shown in Table 1. Patients were referred 
Autologous stem cell transplantation in 
myeloma: the St James’s Hospital experience, 
1997-2003
ABSTRACT 
Background  High-dose treatment with autologous stem cell transplantation (ASCT) has 
become the standard of care for patients with myeloma below the age of 65 years. 
Aims We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT 
in the National Bone Marrow Transplant centre in St James’s Hospital in Dublin 
between 1997 and 2003 inclusive. 
Methods  Clinical and laboratory data were retrieved from patient medical records and 
hospital information management systems.
Results  Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. 
Fifty-seven (95%) patients received anthracycline-corticosteroid combination 
chemotherapy prior to autografting. There was no transplant-related mortality 
(TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 
(53.7%) of those evaluable (n=54 (90%)). The actuarial Progression-Free (PFS) and 
Overall Survival (OS) rates at ﬁve years are 13% and 55% respectively. 
Conclusion  Centre outcome is comparable to published international series and supports 
the use of ASCT in the treatment of this malignancy.
PJ Hayden1, 
A O’Driscoll1, 
N Gardiner1, 
R Swords2, 
J Sargent3, 
F Ni Ainle4, 
A Fortune5, 
PT Murphy2, 
M Leahy3, 
F Jackson4, 
M Ryan 4, 
B Hennessy6, 
M Cahill7, 
GM Crotty8, 
H Enright5, 
E Conneally1, 
E Vandenberghe1, 
SR McCann1, 
PV Browne1
Dept. of 
Haematology1, 
St James’s Hospital, 
Dublin 8; Dept. 
of Haematology2, 
Beaumont Hospital, 
Dublin 9; Dept. 
of Haematology3, 
Mid-West 
Regional Hospital, 
Dooradoyle, 
Co. Limerick.4 Dept. 
of Haematology, 
Waterford Regional 
Hospital, Waterford, 
Co. Waterford; Dept. 
of Haematology5, 
AMNCH, Tallaght, 
Dublin 24; Dept. 
of Haematology6, 
Letterkenny 
General Hospital, 
Co. Donegal; Dept. 
of Haematology7, 
Cork University 
Hospital, Cork; Dept. 
of Haematology8, 
Midland Regional 
Hospital, Tullamore, 
Co. Offaly.
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MYELOMA: THE ST JAMES’S HOSPITAL EXPERIENCE, 1997-2003
O
R
IG
IN
A
L 
PA
P
E
R
IRISH JOURNAL OF MEDICAL SCIENCE • VOLUME 174 • NUMBER 2  27
from nine hospitals: St James’s (n=18), Mid-West 
Regional, Limerick (n=9), Midland Regional, Tullamore 
(n=7), Waterford Regional (n=7), AMNCH, Tallaght 
(n=7), Beaumont (n=6), Letterkenny (n=3), Sligo 
(n=2) and the Royal Victoria, Belfast (n=1). Care of 
patients was shared between referring hospitals and 
St. James’s Hospital. All autograft procedure took 
place at St James’s Hospital.
Eighteen patients were transplanted between 
1997 and 2000, and 42 patients between 2001 and 
2003. The majority (95%) were treated prior to 
autografting with the conventional combination of 
an anthracycline and corticosteroid. Alkylator-based 
regimens such as Melphalan and prednisolone (MP) 
or ABCM (Adriamycin, BCNU, cyclophosphamide and 
melphalan) were given to ten (16.6%) patients. Most 
patients (81.6%) received a single line of chemotherapy 
(median of four cycles) before proceeding to ASCT. 
In terms of disease status after completion of 
chemotherapy, four (7%) achieved a complete 
response (CR - absence of monoclonal protein on 
immunoﬁxation), 46 (76%) a partial response (PR 
- >50% reduction in paraprotein), four (7%) a minor 
response (MR - >25%, <50% reduction in paraprotein) 
and six (10%) stable disease (<25% reduction in 
paraprotein). The median interval between diagnosis 
and transplant was nine months (range: 5-25 months). 
Treatment
Mobilised peripheral blood stem cells (PBSC) were 
used as the source of stem cells in all but the 
ﬁrst ASCT in 1997, who received a combination of 
bone marrow and PBSC. Throughout the seven 
years, four different mobilisation regimens were 
used. Fourteen patients received IEV (ifosfamide, 
epirubicin and etoposide), 21 cyclophosphamide 
4g/m2+G-CSF 5µg/kg and 24 cyclophosphamide 
2g/m2+G-CSF 10µg/kg. One patient was mobilised 
with G-CSF only. Leucapheresis was commenced 
when the peripheral blood CD34+ cell count was 
greater than 20/µL. Harvesting was carried out on 
consecutive days aiming for a minimum target dose 
of 4.5x106/kg CD34+ cells, sufﬁcient to allow for two 
HDT. All PBSC products were cryopreserved with a 
ﬁnal dimethyl sulfoxide concentration of 10% and 
stored at –190oC in vapour-phase liquid nitrogen. In 
12 of the 60 autograft procedures, CD34+ selection 
was performed using the Isolex 300i system (Nexell 
Therapeutics Inc., Irvine, CA, USA), according to the 
manufacturer’s instructions.
The conditioning regimen prior to ASCT consisted 
of busulphan and cyclophosphamide in ﬁve early 
PJ HAYDEN ET AL
Table 1
DEMOGRAPHIC AND CLINICAL DETAILS OF THE PATIENT POPULATION
NUMBER Per cent
PATIENTS 60 100
AGE (MEDIAN, RANGE) 52 (38-66)
<50 years 19 31.6%
51-60 years 30 50.0%
>60 years 11 18.4%
GENDER
Male 39 65.0%
Female 21 35.0%
ISOTYPE
IgG 36 60.0%
IgA 11 18.3%
IgD 1 1.7%
Light chain 9 15.0%
Non-secretory 3 5.0%
YEAR OF AUTOGRAFT
1997 2 3.3%
1998 8 13.3%
1999 4 6.7%
2000 4 6.7%
2001 13 21.7%
2002 10 16.6%
2003 19 31.7%
PRIOR CHEMOTHERAPY
VAD 32 53.3%
Ida-Dex 16 26.6%
Thalidomide-Dex 2 3.3%
Alkylators 10 16.6%
>1 LINE OF CHEMOTHERAPY 11 18.3%
transplants (1997-1998). Since then, all patients 
received melphalan (140-200mg/m2) as a single 
agent. The dose has been divided in two and given 
intravenously over 30 minutes on Days -3 and -2. The 
melphalan dose was reduced from the standard of 
200mg/m2 for six (9.7%) patients with impaired 
renal function.
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G-CSF (5µg/kg) (Neupogen, Amgen) was 
administered subcutaneously from Day +1 until 
two days after neutrophil engraftment (Absolute 
Neutrophil Count (ANC)>0.5x109/l). Routine 
laboratory investigations included daily Full Blood 
Count (FBC) and renal, liver and bone proﬁles. 
Valaciclovir (500mg OD PO) was given as anti-
viral prophylaxis from Day 0. Co-trimoxazole 
(Septrin, 960mg BD PO Mon, Wed, Fri) was given 
as anti-pneumocystis prophylaxis from the time 
of engraftment. Both these medications were 
continued for three months or until the peripheral 
blood CD4+ count was >200/µl. Mycostatin (1ml 
QDS PO) was given as anti-fungal prophylaxis. Broad-
spectrum antibiotic treatment with the combination 
of piperacillin-tazobactam and ciproﬂoxacin 
was used in the event of neutropenic fever. 
Aminoglycosides were avoided due to nephrotoxicity.
Response criteria
Disease response was graded by EBMT criteria.11 
Complete Response (CR) was deﬁned as the absence 
of a detectable monoclonal component in serum or 
in urine by immunoﬁxation analysis, with <5% bone 
marrow plasma cells. A Partial Response (PR) was 
achieved when at least a 50% reduction in initial 
paraprotein levels was achieved and a reduction in 
light chain (Bence Jones) proteinuria by >90% or to 
<0.2g/24h. A Minor Response (MR) was deﬁned as 
a reduction in initial paraprotein levels by 25-49% 
and a reduction in light chain proteinuria by 50-89%, 
but exceeding >0.2g/24h. Apart from CR, PR and MR, 
other categories included No response (NR) and 
Progressive Disease (PD), an increase in serum or 
urine paraprotein by 25%. 
Relapse was deﬁned as recurrence of monoclonal 
protein or bone marrow plasmacytosis if relapse was 
from CR, or a 25% increase from minimal tumour 
mass if relapse was from PR.
Statistical analysis
Data were collected to 1st February 2004. The Kaplan-
Meier method was used to estimate probabilities 
of Progression-Free Survival (PFS, time to disease 
progression) and Overall Survival (OS, time to death). 
RESULTS
Cell doses and engraftment
The median number of CD34+ cells infused was 
3.95x106 CD34+ cells/kg (range: 2.4-18.75x106 CD34+ 
cells/kg).
The median time to neutrophil engraftment 
(>0.5x109/l) was ten days (range: 7-18). The median 
time to platelet engraftment (Plts>50x109/l) was 14 
days (range: 9-39). No signiﬁcant differences were 
seen in the times to engraftment when those of the 
12 patients who received CD34+-selected autografts 
were compared with those of the remaining 48 
patients who received unselected grafts. There was 
no transplant-related mortality. 
Response to autograft
Data to evaluate response were available in 54 
(90%) patients. The absence in certain referring 
hospitals of available bone marrow aspirate or 
serum electrophoresis results for the post-autograft 
period precluded assessment of disease response by 
EBMT criteria in six individuals. Complete (CR) and 
partial (PR) responses to the autograft were seen in 
16 (29.6%) and 29 (53.7%) patients respectively. The 
overall response rate was (CR+PR) was 83.3%. 
Progression-free (PFS) and Overall Survival (OS)
The actuarial PFS rates at three and ﬁve years were 
41% and 13% respectively (Figures 1 and 2). The 
actuarial OS rates at three and ﬁve years were 78% 
and 55% respectively. No signiﬁcant differences were 
seen in the rates of either PFS or OS when those of the 
12 patients who received CD34+-selected autografts 
were compared with those of the remaining 48 
patients who received unselected grafts.
DISCUSSION
This is a retrospective assessment of 60 patients who 
underwent autografting for myeloma at the National 
BMT centre in St James’s Hospital between 1997 and 
2003. Patients were referred from nine hospitals. 
The diagnosis was made and initial chemotherapy 
administered at the referring institution in all 
cases. Early liaison with the BMT centre facilitated 
scheduling of the mobilisation and ASCT procedure. 
An autologous BMT co-ordinator has been appointed 
to organise this tertiary referral service. 
The median age at ASCT was 52 years. Eleven patients 
(18.4%), however, were over 60 years of age, providing 
further evidence of the safety of this treatment in 
an older population. Recent guidelines from the UK 
Myeloma Forum12 and the International Myeloma 
Foundation13 advise that patients aged 60-70 years 
with good performance status may be considered 
suitable candidates for ASCT. There is no evidence, 
however, to support the use of ASCT in those over the 
age of 70 years, and toxicity is clearly increased.14
Patients who are candidates for autografting 
should not be exposed to alkylating agents such 
as melphalan, which are known to damage 
haemopoietic stem cells. Tricot et al found that even 
patients exposed to a median of only four months 
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Figure 1 —
KAPLAN-MEIER 
CURVE ESTIMATING 
PROBABILITIES OF 
OVERALL SURVIVAL 
(OS, TIME TO DEATH).
Figure 2 —
KAPLAN-MEIER 
CURVE ESTIMATING 
PROBABILITIES OF 
PROGRESSION-FREE 
SURVIVAL (PFS, 
TIME TO DISEASE 
PROGRESSION).   
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of prior alkylator therapy showed a signiﬁcant delay 
in platelet recovery post-autograft when compared 
to those who were never exposed.15 In our cohort, 
only ten (16.6%) patients received alkylating agents 
prior to autografting, and of the ﬁve who received 
melphalan, the median number of cycles was three.
The VAD (Vincristine, Adriamycin and 
Dexamethasone) protocol was introduced by the MD 
Anderson group 20 years ago, and was associated 
with a higher response rate and more rapid disease 
control than MP.16 In the last three years, the use 
of the related IDEX (Idarubicin, Dexamethasone) 
regimen has become more widespread.17 Idarubicin 
is an oral anthracycline and facilitates the increasing 
trend towards out-patient-based administration of 
chemotherapy. Sixteen (26.6%) of the more recent 
patients received IDEX-based cytoreductive therapy 
pre-ASCT. Non-myelosuppressive induction therapy 
with oral dexamethasone alone also appears to be 
effective and has been shown not to compromise the 
efﬁcacy of subsequent ASCT.18
Evidence is also emerging that lack of response to 
induction chemotherapy does not seem to preclude 
a successful ASCT. Kumar et al at the Mayo Clinic 
compared 50 patients with primary refractory 
disease and 101 patients with chemosensitive 
disease in term of subsequent response to ASCT.19 
Ten (20%) refractory patients and 35 (35%) in the 
chemosensitive group achieved CR. The estimated 
one-year PFS rates were 70% and 83%, respectively. 
These results suggest that the option of ASCT should 
be considered in all younger patients with myeloma 
regardless of response to initial induction therapy. 
Six (10%) patients in our cohort had refractory (i.e. 
stable) disease after initial induction chemotherapy. 
More prolonged follow-up will allow for the PFS rate 
of this group to be compared with that of those who 
responded to initial treatment.
In general, stem cells should be collected and 
cryopreserved as soon as the best possible response 
has been obtained. Mobilisation of PBSC can be 
achieved by chemotherapy, myeloid growth factors 
or a combination of the two as in our group.20 Three 
sequential mobilisation protocols were in use during 
this period: (1) (IEV) Ifosfamide, Epirubicin, Etoposide 
(VP16), (2) Cyclophosphamide 4g/m2+G-CSF 5µg/kg, 
and (3) Cyclophosphamide 2g/m2+G-CSF 10µg/kg. 
In an analysis of variables inﬂuencing the kinetics 
of engraftment, the minimal threshold dose of 
cells necessary for prompt engraftment was >2x106 
CD34+ cells/kg body weight in patients who had 
received up to two years of prior chemotherapy.15 The 
median cell dose returned to patients in our cohort 
was 3.95 x106 CD34+ cells/kg.
Attempts have been made to purge myeloma cells 
from grafts using positive selection for CD34, an 
antigen expressed on stem cells but not by the 
myeloma clone.21 While this form of selection has 
been shown to reduce the malignant cell content 
of the graft by two to 4.5 logs without adversely 
affecting the rate of engraftment, long-term follow-
up of a randomised study failed to show any survival 
advantage.22 It also appears that such selection is 
associated with a delay in immune reconstitution.23 
As a result, only 12 of the early patients received CD-
34-selected grafts. The grafts from the remaining 48 
patients did not undergo any manipulation.
Two regimens were employed for conditioning. 
Five early patients received busulphan and 
cyclophosphamide. The other 55 patients received 
melphalan (140-200mg/m2). A treatment-related 
mortality rate of 25% has since been reported 
in a Seattle series that used busulphan-based 
conditioning.24 In a randomised trial comparing 
melphalan alone with the combination of melphalan 
and TBI, there was no TRM in the melphalan arm.25 
Consensus now exists that single-agent melphalan 
(200mg/m2) is the recommended conditioning 
regimen.12, 13 Although most (89%) patients received 
full dose melphalan (200mg/m2), the dose was 
reduced in six cases (three at 180mg/m2 and three 
at 140mg/m2) due to renal impairment. Badros et 
al have shown that intermediate dose melphalan 
(140mg.m2) is as effective as full dose (200mg/2) 
but is associated with less toxicity in patients with 
impaired renal function.26 Recent results from this 
group suggest that dialysis-dependent renal failure 
can be reversed by ASCT in some patients.27 
Patients received G-CSF (5μg/kg/day) from Day+1 
until myeloid engraftment. Recovery of the 
neutrophil count (>0.5x109/L) occurred at a median 
of Day +10 (range 7-18). In a recent single-centre 
report of 127 patients who underwent ASCT for 
myeloma where most (86%) did not receive G-CSF, 
neutrophil engraftment was achieved at a median of 
Day +16 (range 10-35).28 While no randomised data 
exist, the reduced duration of neutropenia may have 
contributed to the absence of TRM in our series. 
Fifty-four patients (90%) were evaluable for 
disease response post-ASCT. According to EBMT 
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criteria, almost a third of patients (29.6%) achieved 
a complete response. The attainment of CR is 
predictive of longer PFS and OS.28, 29 In a study of 
59 patients, Nadal et al found those who achieved 
CR had a PFS (median 47 vs. 36 months) and an OS 
(median not reached (at 76 months follow-up) vs. 60 
months) signiﬁcantly longer than those attaining 
a lower degree of response.29 As most of the ASCT 
procedures were done in 2002-2003, the effect of 
attaining CR on PFS and OS in our cohort will be 
assessed after longer follow-up.
Autografting clearly represents a therapeutic 
advance. It is not, however, a curative treatment. 
Although the Kaplan-Meier curve for Overall 
Survival (OS) (Figure 1) appears to suggest a plateau 
after 50 months, this is more likely to reﬂect the 
small number of patients who have achieved this 
degree of follow-up at this point. The experience 
of all large autografting trials to date is one of 
progressive disease reactivation. Both PFS and 
OS decline steadily over time. For the bulk of 
patients, autografting therefore remains a palliative 
procedure. The median PFS was 31 months. Post-
ASCT care includes monthly attendance at the 
haematology day-ward for intravenous zoledronic 
acid, a bisphosphonate shown to decrease the 
incidence of skeletal-related events (pathologic 
fracture, spinal cord compression, radiation therapy, 
or surgery to bone) .30 Periodic clinical assessment 
is also required to detect any evidence of disease 
progression. The pattern of reactivation of disease 
post-ASCT is varied. In a follow-up of 560 patients in 
the Spanish myeloma transplant registry, 280 (52%) 
had relapsed or progressed at a median follow-up 
of 23 months.31 Most patients had a progressively 
increasing paraprotein in addition to different 
clinical symptoms, mainly osteolytic lesions. 40 
(14%) patients, however, relapsed with multiple 
plasmacytomas only. Six (2%) patients fulﬁlled 
criteria for plasma cell leukaemia. A similar spectrum 
of presentations of relapse was seen in our cohort. 
This highlights the need for thorough post-ASCT 
assessment including questions regarding bone pain, 
examination for evidence of plasmacytoma, serial 
monitoring of any monoclonal paraprotein, blood 
ﬁlm review and diagnostic imaging.
No tandem autografts were performed at St James’s 
Hospital during this period. Sufﬁcient stem cells 
have, however, been collected to allow for the 
option of a second autograft in the event of disease 
reactivation in a medically ﬁt individual who is felt to 
be appropriate for this option.
In our cohort, actuarial OS at ﬁve years is 55%. 
This reﬂects both re-treatment with conventional 
combination chemotherapy and the recent 
introduction of novel agents such as Thalidomide. 
When employed in heavily pre-treated patients, this 
latter drug was reported as having a response rate of 
32%.32 This represents the ﬁrst compound in a new 
class of agent, immunomodulatory drugs (IMiDs), 
which target the myeloma clone through a number 
of pathways including anti-angiogenesis, disruption 
of the cell-stroma interaction and cytokine down-
regulation. By combining IMiDs with other new 
drug classes, such as proteosome inhibitors, durable 
disease control may be a realistic goal.33
In summary, autografting represents a signiﬁcant 
advance in the care of patients with myeloma. 
When widely applied within a healthcare system, 
it has been shown to result in prolonged survival 
for the total patient population aged less than 60 
years.34 The procedural complications and outcome 
data for our group are comparable with recently 
published series; the median survival of patients 
who underwent ASCT in the myeloma VII trial was 
54.1 months.8 Future advances must address residual 
disease post-ASCT. 
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INTRODUCTION
IHPS is a condition affecting young infants, in which 
the antropyloric portion of the stomach becomes 
abnormally thickened and manifests as obstruction 
to gastric emptying.1 The incidence is approximately 
2-5:1,000 with a peak incidence of 3-6 weeks. The 
aetiology is unknown. Infants typically present with 
non-bilious, projectile vomiting. Clinical diagnosis 
relies upon the palpation of a thickened pylorus 
or olive. Barium meal features include a narrow 
and elongated pylorus; the so-called string sign. In 
addition there is compression of the duodenal bulb 
and indentation of the gastric antrum (shoulder 
sign). Ultrasound ﬁndings include an elongated 
canal of 15-18mm (Figure 1) and transverse muscle 
thickness above 3mm in diameter (Figure 2).2
METHODS
Using the Hospital Inpatient Enquiry Database 
(HIPE), all patients with a diagnosis of IHPS from 
January 1992 to June 2003 were included. There were 
157 patients; 126 male and 31 female (M: F, 4.06:1). We 
then consulted the Radiology Information System 
(RIS) and determined which of these patients had 
radiology investigations performed, namely barium 
meal and/or ultrasound. For those patients who had 
radiology performed, we recorded the ultrasound 
measurements, where available, and whether the 
results were diagnostic.
RESULTS
Of 157 patients, 38 (24%) were investigated with 
barium meal and 56 (36%) with ultrasound. Twenty-
one patients (13%) had both barium meal and 
ultrasound performed.
In the barium group of 38 patients, three patients 
were excluded, as one had their barium performed 
prior to admission, one barium meal was unreported 
and the other was performed post-operatively. Thirty-
ﬁve (22% of total sample) patients of this group were 
eligible for consideration. Twenty-four (68% of these 
35 patients) were reported as deﬁnitively diagnosing 
pyloric stenosis, with the remainder not yet reaching 
diagnostic criteria.
In the ultrasound group of 56 patients, two patients 
were excluded as one ultrasound was performed 
prior to admission and one was unavailable for 
Changing trends in the management of 
Infantile Hypertrophic Pyloric Stenosis- an 
audit over 11 years
ABSTRACT 
Background  This article is a follow-up to an audit performed by the Department of 
Surgery and published in the Irish Journal of Medical Science in 1996. This audit 
reviewed all cases of Infantile Hypertrophic Pyloric Stenosis (IHPS) operated on over 
22 years up to 1991.
Aims We aim to demonstrate that radiologic investigations, namely barium meal and 
ultrasound, have been increasingly employed in the diagnosis of IHPS. In addition, 
ultrasound is now the investigation of choice.
Methods  We have reviewed all cases of IHPS, at the same institution, over the 
subsequent 11 years, with reference to any radiological investigations performed. 
In the previous study, the diagnosis of IHPS was made clinically in 92.6% with the 
remainder diagnosed radiologically.
Results  Over 11 years, 157 patients were diagnosed with IHPS. Male to female ratio was 
4.06:1.  Median age was four weeks (range 1-18 weeks). Twenty-four per cent had a 
barium meal, 36% had an ultrasound and 13% had both performed.
Conclusion  We conclude a change in practice in the management of IHPS with radiology, 
particularly ultrasound, playing an increasing role.
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reporting. This left 54 patients of whom 35 had 
ultrasound alone and 21 had both ultrasound and 
barium. In the group of 35, a deﬁnitive diagnosis 
was made in 30 (86%) cases with the remaining ﬁve 
patients thought to be evolving IHPS.
Of the group that had both barium meal and 
ultrasound (21 patients), barium was used only 
to conﬁrm the diagnosis where unltrasound 
measurements did not yet reach diagnostic criteria.
DISCUSSION
Barium meal features of IHPS are widely accepted. 
There has been much debate as to the acceptable 
size criteria for ultrasound diagnosis of IHPS. 
Currently a pyloric muscle thickness of greater 
than 0.3mm is accepted in most centres. Early in 
its use, the required ultrasound measurements 
for diagnosis were higher.3, 4 This partly explains 
our group of patients who had both barium and 
ultrasound performed, where initial measurements 
did not reach diagnostic criteria. Also, one has to 
consider that IHPS is an evolving condition. Patients 
at the younger end of the age spectrum at the time 
of presentation may not initially meet ultrasound 
criteria. These patients could have either a barium 
meal or an interval ultrasound for conﬁrmation.
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This study indicates changing trends in diagnosis 
of IHPS. In the series by Maher et al in this hospital, 
only 7.4% underwent upper gastrointestinal contrast 
studies and ultrasound was not used.5
In the subsequent 11 years (January 1992 to June 
2003), this has increased to 24% having barium meal 
and 36% having ultrasound performed. The use of 
barium was at its highest early in the 1990s. With the 
exception of 2001, there has been a steady increase 
in the use of ultrasound over time. The decreased use 
of ultrasound in this year was due to local technical 
factors limiting service availability. Almost 90% of 
patients diagnosed with IHPS in 2002 had ultrasound 
performed (Figure 3). This reﬂects international 
trends, with fewer patients with IHPS diagnosed 
solely on clinical grounds and ultrasound playing an 
increasing role.6
Many patients now present early with symptoms 
of IHPS. Accurate clinical diagnosis in patients in 
whom a thickened antropyloric muscle is not readily 
palpable can be difﬁcult. Delay in diagnosis can 
lead to electrolyte imbalance, making the patient 
a suboptimal surgical candidate.1 Ultrasound is 
fast and readily available. Ultrasound can make an 
accurate, early diagnosis, is non-invasive and does 
not involve ionizing radiation. 
In the initial audit performed in this hospital, 
approximately 90% of the patients were diagnosed 
clinically whereas in the last year of our study 
almost 90% of patients had ultrasound performed. 
Ultrasound imaging is now the primary tool to 
diagnose IHPS.
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INTRODUCTION
In recent years, there have been reports of a 
reduction in the number of surgical procedures for 
glaucoma performed in the United Kingdom.1, 2 There 
are also reports of increases in cataract surgery being 
performed,3, 4 as well as a reduction in strabismus 
operations.5 This information may be relevant for 
planning resource allocation in ophthalmology in 
Ireland. We studied the reported national ﬁgures for 
ophthalmic surgery in Ireland over the past eight 
years to report changes in emphasis in 
ophthalmic surgery.
METHODS
A search of national ﬁgures of ophthalmic operations 
in the Republic of Ireland was performed. We used 
Hospital In-Patient Enquiry (HIPE) data supplied to us 
by the Economic and Social Research Institute (ESRI), 
Dublin, Ireland.6
The HIPE system is a computer-based health 
information system designed to collect clinical data 
on discharges in acute hospitals in Ireland. It was 
established in 1971 and by 1990 had 45 participating 
hospitals with an estimated response rate of 54.8%. 
However, by 1999 there were 60 participating 
hospitals with an estimated response rate of 94.2%.6
Search results are accompanied by estimated 
coverage of the system for each year. The coding 
scheme used was the International Classiﬁcation 
of Diseases, 9th Revision, Clinical Modiﬁcation (ICD-
9CM).6 HIPE data include both in-patient and day 
care surgery performed in theatre. 
Search method
The ICD-9CM codes used for the search are 
illustrated in Table 1. Entries are coded as discharges 
with up to 4 procedures included for each event. 
The number of procedures performed was taken 
as the number of discharges that had the included 
procedures performed. For example, a retinal 
detachment case may have several procedures 
performed but nevertheless would only be included 
as one discharge. 
All searches were for the years 1994 to 2001 inclusive. 
The search was performed in December 2002 to 
allow the greatest possible inclusion of data from 
2001. These operations were chosen as they represent 
the bulk of the workload in ophthalmic surgery. 
RESULTS
Overall, the total number of all discharges included 
was 76,337. There was a 24% increase in the number 
of procedures during the observed period, from 8,857 
to 11,005.
 The average sensitivity of coverage was 94.5% 
(range 91-96%) according to Department of Health 
estimates. The results of the search are shown 
in Table 2.
Trends in Ophthalmic Surgery in Ireland
ABSTRACT 
Aims This study was designed to document the changing trends in ophthalmic surgery in 
acute public hospitals in the Republic of Ireland over the years 1994 to 2001.
Method  We obtained Hospital In-Patient Enquiry (HIPE) data returned from the major 
acute public hospitals to the Economic and Social Research Institute. We searched 
for cataracts, glaucoma, retinal detachment, strabismus, corneal transplant and 
repair of perforating injuries of the globe.
Results  There was a 24% increase in the total number of the searched operations 
occurring during the study period, from 8,857 procedures in 1994 to 11,005 in 2001. 
In 2001, cataract surgery alone counted for 82% of all procedures performed. There 
was a large increase in cataract (49%) and vitreo-retinal procedures (41%) reported 
between 1994 and 2001. Conversely, a large fall in trabeculectomy (67%), strabismus 
(63%) and corneal transplant (52%) procedures occurred during the study period.
Conclusion  These data suggest that surgical numbers in ophthalmology in Ireland are 
increasing and the relative proportions are changing.
TRENDS IN OPHTHALMIC SURGERY IN IRELAND
O
R
IG
IN
A
L 
PA
P
E
R
IRISH JOURNAL OF MEDICAL SCIENCE • VOLUME 174 • NUMBER 2  37
Table 1
ICD-9CM CODES AND DESCRIPTION OF DIAGNOSES AND PROCEDURES 
ASSOCIATED WITH COMMON OPHTHALMOLOGY SURGICAL  PRACTICE
PROCEDURE ICD-9CM DESCRIPTION OF PROCEDURE PERFORMED OR DIAGNOSIS ICD-9CM CODE
Removal of an eye
Evisceration of eyeball
Enucleation of eyeball
Exenteration of orbital contents
16.3
16.4
16.5
Primary repair of a ruptured globe
Suture of corneal laceration
Suture of laceration of sclera
Repair of rupture of eyeball
Other repair of injury of eyeball or orbit
11.51
12.81
16.82
16.89
Corneal transplants
All forms of corneal transplant 
excluding pterygium excision with 
corneal graft
11.60 to 11.69
Strabismus operations All types of ocular misalignmentOperations on extraocular muscles
378.00 to 378.9
15.0 to 15.9
Trabeculectomy Trabeculectomy ab externo 12.64 
Vitreo-retinal procedures 
Repair of retinal detachment with 
scleral buckling and implant
Other repair of retinal detachment
Operations on vitreous
Other removal of vitreous
Other mechanical vitrectomy
 
14.4
14.5
14.71
14.72
14.74
Cataract extraction
Cataract 
Congenital cataract
Cataract extraction
366
743.30-743.34
13.11-13.69
Table 2
NUMBER OF DISCHARGES WITH SEARCHED PROCEDURES RECORDED FROM HIPE DATA
YEAR
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(%
)
1994 99 116 148 636 1213 575 6,024 46 91
1995 99 132 174 723 1069 646 6,377 37 95
1996 98 120 129 664 1,091 640 6,722 29 96
1997 104 94 118 579 923 701 6,737 25 96
1998 80 97 109 438 750 624 6,874 37 95
1999 107 115 94 312 731 732 6955 36 95
2000 88 102 91 290 702 733 8,352 40 94
2001 69 112 71 209 691 811 9,011 32 95
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Figure 1 — 
NUMBER OF 
DISCHARGES WITH 
PROCEDURES OF 
CATARACT SURGERY 
COMPARED TO 
TOTAL NUMBER 
OF ALL INCLUDED 
PROCEDURES FROM 
1994 TO 2001
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Figure 2 — 
NUMBER OF 
DISCHARGES WITH 
PROCEDURES OF 
TRABECULECTOMY 
OR STRABISMUS 
OPERATIONS 
PERFORMED FROM 
1994 TO 2001
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Cataract operations alone accounted for 75% of all 
the ophthalmic discharges retrieved. Comparing 
2001 to 1994,there was a 49.5% increase in cataract 
surgery from 6,024 to 9,011 (Figure 1). There was a 41% 
increase in the number of vitreo-retinal discharges in 
the same period. Meanwhile, there was a 43%, 52% 
and 67% reduction in discharges with strabismus, 
corneal transplant and trabeculectomy procedures 
performed respectively (Figure 2). Little change was 
noted in the number of eyes needing enucleation or 
perforating eye injury repair.
DISCUSSION
This report studies the nationally recorded 
ophthalmology surgical practice acute hospitals in 
the Republic of Ireland. The ﬁgures used are the HIPE 
data returned by acute public hospitals in Ireland. 
These ﬁgures show some procedures are increasing 
in incidence while others decrease. This adds support 
to the accuracy of these ﬁgures.
Our ﬁgures show an increase in the occurrence 
of cataract surgery. This may reﬂect, among other 
things, the ageing population. The number of 60-64-
year-olds in the Republic of Ireland (in thousands) 
has increased from 136.4 in 1995 to 148 in 2000 
(Central Statistics Ofﬁce, Dublin).
The overall number of these procedures performed 
has shown an increase. The number of day cases 
reported in all specialities in the Republic increased 
from 132,295 (23.5%) in 1994 to 246,531 (32.8%) in 
1999. 6 There has been a tendency towards dedicated 
day surgery units in Ophthalmology. This may have 
facilitated an increase in the number of cataract 
operations performed.
Cataracts in the paediatric population represent a 
difﬁcult challenge in ophthalmology 7. The average 
number of operations performed for congenital 
cataracts was 35.2 (range 25 to 46). This probably 
suggests that treatment of this condition should be 
performed in specialised units.
The number of trabeculectomies performed 
has dropped in recent years, coinciding with the 
introduction of newer topical medications for 
glaucoma.1, 2 In Scotland, operations for glaucoma fell 
45.9% between 1994 and 1999, which closely reﬂects 
Irish data.2 The reduction in strabismus procedures 
may be due to better refractive management of 
children in the out-patients situation and better 
overall child health.5 
The decrease in trabeculectomy and strabismus 
operations has been more than compensated for by 
an increase in cataract numbers. The net result is an 
increase in demand for ophthalmologic services, both 
in Ireland and in the United Kingdom.8
This information may help in the planning and 
provision of ophthalmology services in the future.
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INTRODUCTION
The Hospital Inpatient Enquiry system (HIPE) is a 
computer based health information system that 
collects data on discharges from 62 acute public 
hospitals in Ireland (Tables 1 and 2). It is the largest 
of eight national health information systems. The 
original objectives of HIPE as outlined in the recent 
HIPE report1 were to provide a standard minimum 
dataset on inpatient morbidity and mortality, to 
facilitate analysis of hospital activity, and to allow 
comparisons between countries. Arguably, one of the 
most important subsequent uses of HIPE data has 
been in the estimation of the casemix adjustment 
for acute hospital budgets. HIPE data have also been 
used for patient care studies, epidemiological studies, 
monitoring practice, planning, service provision, and 
quality assurance studies. 
As HIPE was not explicitly designed as a research 
tool, limitations have been encountered. This paper 
examines the practical, system and policy limitations 
surrounding HIPE from the perspective of public 
health researchers with a view to suggesting 
changes which would increase the usefulness of 
HIPE as a research and planning tool, particularly 
in the context of the current health service reform 
programme. Reference is also made to the recently 
published National Health Information Strategy.2
Practical issues
Data quality
There are three criteria by which data quality is 
assessed: coverage, completeness and accuracy.3 
Coverage refers to the proportion of the total 
activity recorded by a system3 and relates to both 
the number of hospitals covered and data coverage 
within these hospitals. The HIPE report1 states that 
HIPE collects data from all acute public hospitals 
nationally although this has been amended on 
the HIPE website (http://www.esri.ie/) to reﬂect 
the inclusion of data from two private hospitals. 
However, there remain other private hospitals that 
are not included in HIPE. The term ‘acute hospitals’ 
is not well deﬁned as can be seen from Tables 2 and 
3 which highlight the discrepancies between the 
Department of Health and Children’s classiﬁcation of 
an acute hospital4 and that used by HIPE. As overall 
coverage of the system is unclear this may lead 
to an underestimation of population based rates 
and selection bias.5 No mention of these potential 
problems is made in the HIPE report. Coverage in 
the HIPE report refers to data coverage, that is, the 
per centage of discharges from hospitals included 
in the HIPE system that are captured by HIPE. This 
has increased from 55% in 1990 to over 95% in 
1998,1 partially due to improved training and the 
Using HIPE data as a research and planning 
tool: limitations and opportunities
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employment of dedicated HIPE coding staff within 
each hospital. The quantity of data collected has also 
increased with additional diagnosis and procedures 
ﬁelds, extra consultant ﬁelds, and recording of the 
number of intensive care and private care days.1 
HIPE, however, does not record any activity in the 
outpatients or emergency departments. This limits 
the extent to which the full activity of hospitals 
can be examined. For example, a study using HIPE 
to assess the burden of alcohol on acute hospital 
services was limited to assessing the impact on 
hospital admissions only,6 in spite of the fact that a 
high proportion of accident and emergency contacts 
are alcohol related.7
Completeness of data refers to the proportion of 
records that have an entry in any speciﬁed ﬁeld.3 
Incompleteness can render some ﬁelds useless. One 
solution is to make the entry of data for certain ﬁelds 
compulsory, although this can lead to the overuse of 
default codes. For example, in a study to develop a 
more sensitive empirically based model of demand 
for hospital inpatient care for small areas, it emerged 
that the use of “dump” postcodes in the UK resulted 
in biased data that had to be omitted.8 The HIPE 
report makes no mention of data completeness. 
Accuracy refers to the extent to which completed 
records are valid,3 that is, whether they measure the 
characteristics that they were intended to measure.9 
While HIPE validation is reported as taking place both 
at hospital level and centrally, there is no reference to 
validation using hospital charts, to an examination 
of inter-coder variation or to any external audit. An 
independent study at a large Dublin hospital in 1995 
showed an inaccuracy rate for primary diagnosis 
of 41% and the omission of 44% of secondary 
diagnoses.10 Three more recent studies looking at 
the management of acute myocardial infarction,11 
the epidemiology of leptospirosis12 and rotavirus,13 
found discrepancies between their prospectively 
recorded or laboratory recorded ﬁgures and the HIPE 
ﬁgures. These ﬁndings highlight the fact that there is 
no method of detecting data that meet consistency 
checks but may be incorrect. 
Events versus patients
The HIPE system records the number of inpatient and 
day-case events rather than the number of patients. 
While it is possible to identify some readmissions 
through individual hospital medical record numbers 
or through admission codes, the inability to be sure 
of identifying them all has caused difﬁculties in 
many studies. A unique personal identiﬁer would 
enable readmissions to be easily identiﬁed from 
event level data and, if introduced for every citizen, for 
all medical, social and administrative data, a greater 
array of research and planning activities would be 
possible. Examples of studies which could have 
been better accommodated include development 
of a needs based resource allocation model using a 
population level database (O’Loughlin R. Unpublished 
thesis, TCD, 2004) and determination of incidence and 
prevalence of diseases, for example, leptospirosis,12 or 
opiate drug use.14 
Socio-economic group variable
The lack of an explicit socio-economic group variable 
reduces the usefulness of HIPE data in examining 
inequalities and in exploring the determinants of 
health. A report on inequalities in health in Ireland 
was unable to examine socio-economic gradients 
in hospital events.15 Medical card status is the only 
HIPE variable that could be used as a proxy for socio-
economic group although the recent addition of HIPE 
ﬁelds that classify health coverage into private, medical 
card-holder or neither may provide a better proxy. 
Small area coding
The only patient address information recorded 
by HIPE is county of residence. The lack of a small 
area identiﬁer such as an electoral division code 
means that it is not possible to use spatial models 
that could help in the planning of services, or to 
differentiate between illness patterns at sub-county 
level. A National Hospitals Ofﬁce is proposed as part 
of the health service reform programme.16 This may 
necessitate deﬁning catchment areas for each acute 
hospital to assist with planning services. Experience 
has shown that lack of data coded to small area 
creates difﬁculties in deﬁning hospital catchment 
areas.17 Small area coding of HIPE data would assist 
in the development of a small area based resource 
allocation model similar to the York model in 
England,18 and would eliminate the need to geo-code 
data for speciﬁc projects such as the recent exam-
ination of congenital anomalies and landﬁll sites.19
System issues
Access and Conﬁdentiality
Requests for HIPE data must be made in 
writing to the ESRI HIPE manager and these 
are dealt with while respecting conﬁdentiality 
constraints protecting patient, doctor and hospital 
identiﬁcation.1 In general, only access to aggregate 
statistics is provided by either the ESRI or the Public 
R O’LOUGHLIN ET AL
42 IRISH JOURNAL OF MEDICAL SCIENCE • VOLUME 174 • NUMBER 2
O
R
IG
IN
A
L 
PA
P
E
R
Health Information System.5 Event data with a 
limited number of ﬁelds are occasionally provided 
and researchers are required to sign a conditions of 
use statement. In some circumstances additional 
data may be provided directly by the Department 
of Health and Children, particularly for work 
undertaken on their behalf. Contributors to HIPE, 
such as hospital based clinicians and managers, can 
obtain HIPE data for their individual hospital. Some 
health boards have access to HIPE data for their 
residents. However, data at health board level can 
only have limited use as there are no national data to 
which activities and outputs can be compared or to 
which reductions in inequalities can be measured.
Reporting
The 1990-1999 HIPE report, published in 2002, is the 
only ofﬁcial HIPE report ever published. It presents a 
series of frequency charts of discharges by hospital 
and Diagnostic Related Groups with no statistical 
analyses and limited commentary. As the data 
are not age, sex, or casemix adjusted, comparison 
between hospitals is not valid so its utility is limited. 
Reports pertaining to subsequent years have not 
yet been published. Annual reports, which are a 
feature of most other Irish databases, would be 
useful for identifying trends in hospital activity, for 
highlighting new developments, and for reporting on 
coverage, completeness and accuracy. Consultation 
with HIPE users is essential in order to maximise the 
effectiveness of the reports. 
Timeliness
Timeliness of data is particularly important and HIPE 
data are theoretically available six months after the 
year’s end. In practice, the data may not be available 
for several more months. For research purposes, 
this timescale is not problematic but it may cause 
difﬁculties for service planners.
Policy issues
Hospital and consultant identiﬁers are not provided 
to HIPE users for conﬁdentiality reasons. Another 
stated reason for not providing identiﬁers is to 
prevent the production of hospital or consultant 
league tables. The difﬁculty with league tables is that 
their results can be widely misinterpreted unless the 
data are properly standardised for patient variables 
such as age, sex, socio-economic group, casemix, 
and elective versus emergency surgery. However, 
there have been attempts to create league tables in 
Ireland from ﬁgures garnered under the Freedom of 
Information Act.20
Positive developments from standardised league 
tables that are part of a performance indicators 
programme in the UK21 show that hospitals that 
performed well were rewarded with increased 
autonomy and hospitals that performed poorly 
were supported to improve standards.21 On the other 
hand, perverse incentives created by performance 
indicators exist; for example, reports of reduced 
surgery on high risk cases,22 and changes in recording 
practices to reduce severity adjusted mortality 
rates.23 It is therefore essential that clinicians are 
involved in discussions pertaining to how data 
they produce are used and presented.24 And it is of 
interest that Spiegelhalter et al.,25 in their review of 
lessons learned from the Bristol inquiry, concluded 
that because ranks are highly sensitive to chance 
variability, ranking institutions is inappropriate. 
They recommend displaying risk adjusted trends 
in outcomes with 95% conﬁdence intervals for 
institutions instead. 
Anonymised data are normally sufﬁcient for research 
purposes, but for planning purposes it would be 
preferable to have identiﬁer data available but only 
with the agreement of the hospitals and consultants 
on access to and use of the data. Appropriately 
standardised comparisons between consultants and 
hospitals could help to improve quality, reduce access 
inequalities and standardise services both locally 
and nationally. For example, Spiegelhalter et al.25 
have shown that statistical analysis of routine data 
sources was able to identify the excess paediatric 
surgical mortality in the Bristol Royal Inﬁrmary.
Recent reports that have fed into the health service 
reform programme, such as the ‘National Task Force 
on Medical Stafﬁng’26 and the ‘Development of 
Radiation Oncology Services in Ireland’,27 required 
detailed information on throughput, accessibility 
and caseloads in order to inform planning decisions. 
Accurate HIPE data that identify hospitals and 
consultants will be required to evaluate these reforms 
and to continue to help inform decision making. 
DISCUSSION
The acute hospital sector receives the bulk of health 
service funding and yet the system measuring its 
activity has several weaknesses. It is important that 
HIPE users have conﬁdence in HIPE data and the 
recent HIPE report may have been a lost opportunity 
to adequately clarify the validation process. HIPE is 
a potentially valuable research and planning tool. 
While one of the original objectives of HIPE was to 
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Table 1
DETAILS OF THE HIPE SYSTEM
THE HIPE SYSTEM DATA COLLECTED BY HIPE
• Computer based health 
information system
• Started in 1971
• Minimum data set
• Records inpatient and 
daycase discharge 
information
• 62 hospitals
• Administered by the 
Economic and Social 
Research Institute (ESRI) 
for Department of 
Health and Children
Administrative data
• Patient name 
(retained within hospital)
• Case reference number and 
hospital number
• Dates of admission and discharge
• Dates of ﬁrst and principal 
procedure
• Day case indicator
• Admission type and admission 
source
• Discharge status and discharge 
destination
• General Medical Services status
• Admitting and discharge 
consultant (encrypted)
• Intensive care days and private 
care days
Clinical data
• Principal and up to 9 secondary 
diagnoses (ICD-9-CM)
• Principal and up to 9 secondary 
procedures (ICD-9-CM)
Demographic data
• Date of birth, sex, marital status
• Area of residence by county
Table 2
NUMBER AND TYPE 
OF HIPE HOSPITALS
 TYPE OF 
 HOSPITAL NUMBER
County 23
General 10
Regional 6
Orthopaedic 6
Maternity 5
Longstay 3
Cancer 2
Private 2
Infectious disease 2
Paediatric 2
ENT 1
Total 62
Table 3
HOSPITALS WHERE A DISCREPANCY EXISTS BETWEEN DOHC 4 AND HIPE 1 CLASSIFICATION OF ACUTE HOSPITAL
 HOSPITAL DOHC HIPE
Ballina District Hospital, Co. Mayo District Acute (county)
Bantry General Hospital, Co. Cork Acute Not included
St. Mary’s Auxillary Hospital, Baldoyle, Dublin Acute Not included
Our Lady’s Hospice, Harold’s Cross, Dublin Not included Acute (long-stay)
St. Mary’s Hospital, Phoenix Park, Dublin Not included Acute (long-stay)
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allow comparisons with other countries, not enough 
has been done by way of validation of the system 
and adjustments to take account of our mixed 
public-private hospital service to allow interpretable 
comparisons with other countries to be made.
The usefulness of the HIPE data could be improved 
by instituting the recommendations outlined below 
which have arisen from this paper. 
We suggest that the Department of Health and 
Children should be responsible for the policy 
orientated recommendations, particularly those 
that have resource implications. These include 
expansion of the system to cover outpatient and 
emergency services, inclusion of data from all private 
hospitals, routine small area coding, adoption of a 
unique personal identiﬁer and a socio-economic 
code. These measures would have the added beneﬁt 
of facilitating comparisons with similar systems in 
other countries which have been hampered hitherto 
by the restrictive nature of the current HIPE system. 
The ESRI operates the HIPE system on behalf of the 
Department of Health. To maximise the use of HIPE 
as a research tool and in particular as a planning tool, 
will require the development of a set of procedures 
in conjunction with participating hospitals and 
consultants. A balance will have to be struck so that 
data are published at the appropriate agreed  level 
of anonymity. In addition, feedback mechanisms 
to hospitals and consultants need to be built in to 
maximise validity and completeness of data.
Further recommendations for the operators (ESRI) 
include regular reports with more in-depth analysis 
of national data, the provision of clear information 
on coverage, completeness and accuracy and a 
system of external audits.
In addition, we recommend that consideration 
be given to making the identiﬁcation of hospitals 
and consultants available in some circumstances, 
particularly for quality control, risk assessment and 
service evaluation both locally and at national level. 
A debate is needed as to who is best suited to carry 
out this research and the new Health Information 
and Quality Authority may be well placed to do this. 
However, if work were to be contracted out to third 
parties, such as academic institutions, restrictions on 
access to data would have to be relaxed. The ability to 
conduct independent research is currently constrained 
due to access difﬁculties to individual level data. 
We envisage that the National Health Information 
Strategy2 will provide a context for these 
recommendations. It is therefore essential that it is 
implemented immediately as its delay is limiting the 
development of a coherent and co-ordinated Irish 
health information infrastructure. 
For the health services reform programme to 
advance, comprehensive, accurate and timely data 
will be required and HIPE will be an important source 
of such information. While a signiﬁcant investment 
will be required to implement the recommendations 
arising from this paper, the improved quality 
and quantity of research are likely to make this 
investment worthwhile.
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INTRODUCTION
Musculoskeletal complaints constitute a major 
reason for patients seeking medical treatment. 
This has been highlighted by the international 
designation of this decade 2000-2010 as ‘The 
Bone and Joint Decade’. This increased recognition 
of the importance of musculoskeletal medical 
practice has brought the issue of the adequacy 
of musculoskeletal medical education to the fore 
in current medical literature. As primary care 
physicians, it is general practitioners who typically 
have the initial responsibility for provision of care for 
many musculoskeletal problems. They may be able to 
manage many of these problems themselves or have 
recourse to referring certain patients for specialist 
orthopaedic or rheumatological assessment. 
International studies have demonstrated that 
symptoms of musculoskeletal problems are second 
only to respiratory system complaints as a reason 
for patients seeking medical attention.1 Although 
the speciﬁc number of patients presenting to an 
individual practitioner is dependent on a large 
number of variables, it has been shown that 
between 15 and 27% of patients presenting to their 
primary care physician do so with a musculoskeletal 
complaint.2,3 A sound knowledge of the basic issues 
and management of musculoskeletal problems is 
therefore essential for all medical practitioners.
Despite this it has been shown that 51% of general 
practitioners reported their training in orthopaedics 
to be inadequate for their current practice while 
paediatric trainees reported orthopaedics as being 
the most inadequate part of their training.4,5 These 
ﬁndings imply that many doctors feel they may be 
inadequately managing musculoskeletal problems 
due to a lack of training in this discipline.
The apparent disparity between the preparedness 
of medical graduates in this discipline and the 
prevalence of musculoskeletal complaints in the 
community prompted us to ascertain the prevalence 
of musculoskeletal complaints presenting to 
Irish general practitioners and to establish the 
attitudes of Irish general practitioners towards 
Relating undergraduate musculoskeletal 
medicine curricula to the needs of 
modern practice
ABSTRACT
Background  International studies have demonstrated signiﬁcant discrepancies between 
undergraduate musculoskeletal curricula and the needs of modern medical practice.
Aims To determine the prevalence of musculoskeletal disorders in primary care, General 
Practitioners, assessment of their undergraduate musculoskeletal training and that 
considered ideal for several clinical skills, and the relative importance of the ability 
to recognise selected clinical presentations.
Methods  A postal survey of 200 General Practitioners using a detailed questionnaire.
Results  The response rate was 50.5%, with respondents being an average 18.5 years in 
practice. They saw a mean 140.3 patients/week (range 10 – 270) of which 17.4% 
presented with musculoskeletal complaints (range 5-50%). Respondents felt their 
musculoskeletal education was poor, with a signiﬁcant difference between it and 
their ideal (p=0.007). The most important skill for a graduating doctor was history 
taking, examination and appropriate investigation of a musculoskeletal problem. 
The most important clinical presentation was recognition of traumatic quadriplegia.
Conclusions  A large proportion of primary care in Ireland is devoted to musculoskeletal 
complaints, however, there are deﬁciencies perceived in undergraduate 
musculoskeletal education. A review of undergraduate musculoskeletal curricula, 
emphasising the clinically relevant aspects of this discipline is needed.
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their own undergraduate training, what aspects 
of musculoskeletal training they consider most 
important, and the relative importance of knowledge 
of various speciﬁc musculoskeletal conditions.
METHODS AND MATERIALS
We performed a postal survey of 200 randomly 
selected general practitioners using a questionnaire. 
There were general questions regarding the 
prevalence of musculoskeletal disorders in their 
practice and other features of the practice (number 
of years in practice, whether group or individual, 
whether urban or rural, total number of patients 
seen per week and whether they had any special 
interest in musculoskeletal problems). 
We then obtained each practitioner’s assessment of 
the training they obtained in medical school and that 
considered ideal for graduates. They were speciﬁcally 
asked to rate on a scale of 1 to 5 the relative importance 
of a range of clinical skills and areas of knowledge 
in musculoskeletal medicine (Table 1). Each topic 
therefore generated an overall score of between 1 and 5 
when the means of these responses were calculated.
A further section was then devoted to the 
practitioners’ assessments of the relative importance 
of the ability to diagnose and treat 57 selected, 
representative clinical presentations (Table 2). This 
was also assessed on a scale of 1 to 5 depending on 
perceived importance.
The results were collated and statistical analysis 
was performed using a commercial programme 
(SigmaStat version 2.0).
RESULTS 
There were 101 replies (50.5%). Further survey 
mailings were not performed. The respondents were 
an average 18.5 years in practice. Rural practices 
accounted for 43% and urban 57% of those who 
replied and 60.1% were in group and 39.9% in 
individual practices. They saw a mean 140.3 patients/
week (range 10 – 270) of which 17.4% presented with 
musculoskeletal complaints (range 5-50%). A third 
(33%) claimed a special interest in musculoskeletal 
medicine. Further analysis of these special interests 
revealed 57% were speciﬁcally in sports related 
complaints, 24% were in back pain and 19% were in 
general and paediatric complaints.
Respondents felt musculoskeletal medicine to be 
important for students; however, the respondents
felt their own musculoskeletal education was poor, 
with a signiﬁcant difference between it and their 
ideal (p=0.007), which was unrelated to time elapsed 
since graduation. 
The most essential skills required were reported 
to be the ability to perform a history, examination 
and appropriate investigation of musculoskeletal 
problem (score 4.46) followed by the emergency 
management of fractures (score 4.44). Embryology 
was considered of academic interest only.
The least well taught topic was the correct 
technique and indications for soft tissue/intra-
articular injections (score 1.77). Of note, all topics 
were rated as poorly taught except for anatomy and 
pathophysiology. Even these, however, only scored as 
adequate (score 3.11).
The importance of being able to manage 57 clinical 
musculoskeletal scenarios was also assessed, with 
none being perceived to be of academic interest only. 
Those considered essential were diagnosis and initial 
treatment of (in descending order) quadriplegia, a 
battered child, tendon or nerve injury, septic arthritis, 
congenital dislocation of the hip, degenerative 
disc disease or disc herniation of the lumbar 
spine, slipped upper femoral epiphysis, fracture 
distal radius or scaphoid, fractured neck of femur, 
unstable pelvic fracture, multiple injuries requiring 
assessment and treatment using ATLS principles and 
Perthes disease of the hip.
The only scenario reported to be of borderline 
usefulness was the ability to diagnose and manage 
a genetic condition affecting the musculoskeletal 
system such as muscular dystrophy.
DISCUSSION
The ﬁnding here that a large proportion of primary 
care is devoted to musculoskeletal complaints 
is consistent with the results of similar studies 
internationally.2,3,8 Given this relatively high 
prevalence, the importance of the ability to deal 
adequately with these complaints is obvious. 
However, there appear to be deﬁciencies in 
the undergraduate instruction received by the 
population sampled here, with a signiﬁcant 
difference being reported between the quality of 
instruction received and that considered ideal. 
The general practitioners sampled here felt their 
undergraduate musculoskeletal instruction to be 
typically poor. Freedman et al speciﬁcally tested 
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the adequacy of medical school education among 
graduates, and found that 82% failed to demonstrate 
basic competency in a validated examination of 
fundamental concepts.6 As studies have shown 
that medical school represents the only training in 
musculoskeletal medicine received by up to 56% 
of all primary care physicians, there is obviously 
an imperative here to address the adequacy of the 
undergraduate curriculum.4
The results of the current study clearly demonstrate 
that practitioners rate the teaching of practical 
skills such as clinical diagnosis, musculoskeletal 
interventions and emergency management as 
signiﬁcantly more important than the more 
academic aspects of the topic such as genetics or 
biochemistry. These practical topics are not perceived 
as being well taught in the current system and new 
models of teaching and the emphasis on particular 
subjects in medical school need to be assessed. These 
ﬁndings are also supported by the great importance 
the practitioners placed on the ability to correctly 
diagnose and manage many acute and traumatic 
musculoskeletal disorders.
TABLE 1
QUESTIONNAIRE/RATING SCALE ON 12 CLINICAL SKILLS AND AREAS OF KNOWLEDGE IN MUSCULOSKELETAL TRAINING.
Question 1:  Do you feel your undergraduate education preparation in the following areas was:
1 = Inadequate
2 = Poor
3 = Adequate
4 = Good
5 = Excellent
Question 2:  How important is this subject in undergraduate instruction?
1 = Of academic interest only and will have little or no use in clinical practice
2 = Knowledge or ability in this subject area may be beneﬁcial in clinical practice
3 = A basic knowledge or ability in this subject area is important but not essential
4 = A clear understanding of this subject or ability to perform this task is important
5 = Knowledge of this subject or ability to perform this task is critical
SUBJECT Q. 1 Q. 2
Musculoskeletal Anatomy
Pharmacology pertaining to musculoskeletal disorders
Genetics of musculoskeletal disorders
Pathophysiology of common musculoskeletal disorders (e.g. OA, RA, osteoporosis etc.)
Embryology of the musculoskeletal system
Neurological disorders and their effect on the musculoskeletal system
Biochemistry of musculoskeletal disorders
Microbiology of infective musculoskeletal disorders 
(e.g. tetanus, septic arthritis, osteomyelitis etc.)
History, examination and appropriate investigation of musculoskeletal problem
Emergency management of fractures 
(e.g. manage & clear c-spine in trauma, emergency splintage of  fractures etc.)
Demonstrate correct technique and explain indications for 
soft tissue/intra-articular injections
Indications for and interpretation of XRays
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TABLE 2
RATING SCALE FOR CLINICAL PRESENTATIONS
Question: How important is it for a graduating medical student to be able to diagnose and appropriately 
treat a patient with the presenting complaints listed below? 
5 = Critical
4 = Very important
3 = Helpful
2 = Potentially beneﬁcial
1 = Academic interest only
1.
Low back pain radiating into foot (degenerative disc disease of the lumbar spine; disc 
herniation, radiculopathy)
2. A dislocatable hip at birth (congenital dislocation of the hip)
3.
An inability to move his/her upper and lower extremity following a neck injury 
(quadriplegia)
4. An acutely painful swollen joint (septic joint)
5. Pain and swelling of a joint (OA, RA, gout, pseudogout)
6. A child with inadequately explained injuries (battered child)
7. Multiple injuries requiring assessment and treatment using ATLS principles
8. A fracture through a growth plate (physeal injury)
9.
A deep laceration to the forearm and abnormal hand movement or sensation (tendon, 
nerve, muscle, vessel injury)
10.
Shoulder pain following an acute injury (AC joint disruption, shoulder dislocation, fracture 
clavicle or prox humerus)
11.
Haemodynamic instability and an unstable pelvis following a high energy trauma 
(unstable pelvic fracture)
12. Hip/groin pain in a 10-year-old (slipped upper femoral epiphysis)
13. Neck pain after being rear-ended in RTA (musculo-ligamentous sprain of the cervical spine)
14. Wrist pain following a fall (fracture distal radius, scaphoid)
15.
Pain and swelling of elbow region after an acute injury (dislocated elbow, radial head #, 
olecranon #, supracondylar # distal humerus)
16.
Pain in the hip region following an acute injury (inter/subtrochanteric #, femoral neck #, 
dislocated hip, acetabular #, pubic rami #)
17. Low back pain after lifting an object (acute lumbar strain, disc herniation)
18.
Swelling and pain in the knee following an acute injury (ant. cruciate lig. tear, medial 
collateral lig. tear, meniscal tear, tibial plateau #)
19. Paediatric multiple trauma victim
20.
Pain and swelling in the ankle region after an acute injury (lat. ankle ligament sprain, 
ankle #, osteochondral #, tibial plafond #)
21. Chronic low back pain (lumbar strain, spondylolisthesis)
22. Chronic neck pain (whiplash, arthritis, cervical stenosis)
23. Hip/Groin pain in a 6-year-old (Perthes disease)
24.
A grossly swollen foot which is minimally painful and a history of diabetes 
(diabetic neuropathy)
25.
Pain and/or numbness in one hand (carpal tunnel syndrome, nerve compression 
syndromes)
CONTINUED OPPOSITE
KJ MULHALL, E MASTERSON
50 IRISH JOURNAL OF MEDICAL SCIENCE • VOLUME 174 • NUMBER 2
O
R
IG
IN
A
L 
PA
P
E
R
TABLE 2 - CONTINUED
RATING SCALE FOR CLINICAL PRESENTATIONS
26.
Knee pain (patello-femoral pain syndrome, osteoarthritis, meniscal tear, RA, 
tendonitis, bursitis)
27.
Pain in the shoulder (subacromial impingement, adhesive capsulitis, rotator cuff tear, AC 
joint arthritis)
28. Neonate failing to move arm after birth (brachial plexus injury)
29. A painful deformed upper arm following an injury (humeral shaft #)
30.
Pain and deformity in the forearm following acute injury (radius & ulna #, nightstick #, 
Galleazzi #, Monteggia #)
31. Hip/groin pain (osteo or rheumatoid arthritis)
32.
Pain over the distal forearm and wrist (De Quervains tenosynovitis, scaphoid non-union, 
radiocarpal arthritis)
33. A toddler with a painful elbow after being picked up (pulled elbow)
34. A child with an acute limp (greenstick #, transient synovitis)
35. Polyarticular arthritis (RA, ankylosing spondylitis)
36. A painless curvature of the spine (idiopathic scoliosis)
37. Pain over the lateral elbow (lateral epicondylitis)
38. Muscle and joint pain throughout the body (ﬁbromyalgia, ﬂu, myositis)
39. Heel swelling and pain after a fall from a height (calcaneus #, heel bruise)
40. Hand pain after striking an object/person (boxers #)
41. Finger pain after accidentally striking it (phalanx #, subungual haematoma)
42. A non-tender soft-tissue mass (soft-tissue tumour)
43. Painful foot following an injury (phalanx #, Lisfranc #, metatarsal #)
44. Pain and swelling in a number of joints (polyarticular arthritis, JRA)
45. A child with abnormal looking feet (in/out-toeing, metatarsus adductus)
46. A deformed foot at birth (clubfoot)
47. Instability and recurrent dislocations of the shoulder 
48. Forefoot pain following repetitive stresses to the area (stress #)
49. Chronic pain in the heel region (plantar fasciitis, heel pain syndrome)
50. An osseous lesion on plain x-ray (bone tumour)
51. A history of recurrent ankle sprains (chronic lateral ankle instability)
52. A deformed great toe including a painful medial ‘bump’ (hallux valgus)
53. Nodularity on the palm and ﬁnger contractures (Dupuytren’s contracture)
54. A congenital spinal abnormality (congenital kyphosis, Scheurmann’s etc)
55. A history of cerebral palsy
56. Deformity of the sternoclavicular joint (SC joint subluxation)
57.
A genetic condition affecting the musculoskeletal system (osteogenesis imperfecta, 
Ehlers-Danlos syndrome, muscular dystrophy)
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Although not the primary objective of the current 
study, many also referred to a lack of formal 
training in this specialty during their postgraduate 
vocational training. In this regard, many of the 
respondents, particularly those with a special 
interest in musculoskeletal problems, indicated that 
they had pursued postgraduate courses of their 
own volition. However, they also expressed concern 
at the difﬁculty in ﬁnding suitable courses for their 
perceived needs. It therefore appears that there are 
deﬁciencies in musculoskeletal medicine training 
across the whole spectrum of medical education.
As mentioned earlier, one third of the general 
practitioners claimed a special interest in 
musculoskeletal medicine. Although studies such 
as this are prone to a selection bias based on the 
interests of those surveyed, this ﬁgure is nonetheless 
an indication of how prevalent musculoskeletal 
problems are. The preponderance of those with 
a special interest, furthermore, identiﬁed sports 
injuries and back complaints as their area of interest. 
This would indicate that a signiﬁcant proportion of 
the problems presenting to general practitioners 
fall into one of these categories. Unfortunately, 
undergraduates typically have little exposure to 
these conditions as these are largely managed on an 
outpatient basis. Also, the relatively new discipline 
of sports medicine in particular has not been the 
focus of much attention in traditional texts and 
curricula. However, such special interests aside, 
the overall results here indicate the rather urgent 
need to reassess the whole range of undergraduate 
musculoskeletal medicine education as currently 
provided by orthopaedic and rheumatologic 
academic services. A more effectively co-ordinated 
interaction between primary care training and these 
services also needs to be achieved. The results further 
emphasise that curricula need to be implemented 
with an emphasis on the common conditions 
encountered in the community.
In conclusion, we have found that musculoskeletal 
complaints constitute a signiﬁcant proportion 
of the workload of general practitioners. Their 
dissatisfaction with the undergraduate training 
received however indicates the need for a review 
of undergraduate musculoskeletal curricula, with 
an emphasis possibly on more common outpatient 
problems, emergencies and physical examination 
and diagnosis. There may also be a place for 
changes in postgraduate vocational training in 
musculoskeletal medicine and the provision of 
relevant postgraduate courses for those practitioners 
wishing to develop a special interest.
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INTRODUCTION
While O’Loughlin et al (2005)1 recognises in the 
introduction that the Hospital Inpatient Enquiry is 
intended to provide a “standard minimum dataset 
on inpatient morbidity and mortality” subsequent 
comment would seem to assume a broader set of 
objectives for this system. It is important, therefore, 
to reiterate at the outset that the HIPE system 
is intended to collect information on discharges 
treated in the inpatient setting. Notwithstanding 
the desirability of being able to track individuals 
through the health system, with it’s establishment 
the HIPE system was never intended for this 
purpose. While the ‘inpatient’ setting has been 
broadened in recent years to include day case 
activity, it was never intended that the HIPE system 
would collect information in the outpatient, A&E or 
community settings. Again, while the establishment 
of information systems in such settings might be 
desirable, such an initiative demands consideration of 
a whole range of factors speciﬁc to the relevant areas.
In Table 1, O’Loughlin et al (2005) list what they call 
‘Data collected by HIPE’. This listing is incomplete 
and out of date. In Table 1 here, a complete and up to 
date listing of data collected by HIPE is presented. 
Practical Issues
Data quality
It is extraordinary that nowhere in the paper by 
O’Loughlin et al (2005) is there any mention of the 
HIPE software (Windows HIPE and Windows HIPE 
Reporter). Custom designed software for data entry 
and reporting of HIPE data have been produced 
by the ESRI’s HIPE & NPRS Unit. An independent 
review of clinical coder training programs and data 
quality audit procedures commissioned from the 
University of Sydney in 2004 went so far as to state 
that “the ‘ace’ in the Unit’s pack of data quality 
initiatives is the HIPE computer system”.2 Every HIPE 
hospital uses the same software, standardised to 
the same version for the entry of HIPE data. This 
software is updated regularly. Integrated within this 
software are a whole range of procedures directed 
at safeguarding data quality. Automated edits and 
validations enable hospitals to correct errors at the 
source and are performed on individual data ﬁelds as 
data are entered in the system. There are also inbuilt 
combination checks between two or more data ﬁelds 
and ﬁnal cross comparisons between all data ﬁelds 
when data entry for the episode of care has been 
completed. Table 2 gives an indication of the range 
of data quality and consistency checks integrated 
within the HIPE software. Messages are displayed 
to prompt or guide the user in correcting any errors. 
Fields are also colour coded and ‘red’ indicates the 
ﬁeld with an error. 
Flags are inbuilt to the data entry software to reject 
certain codes or coded combinations. They also allow 
users to conﬁrm, endorse or explain their choice of 
codes. Some ﬁelds allow the user to enter a textual 
explanation of why they selected a certain code 
(particularly the .9 unspeciﬁed codes). Two special 
ﬂags, audit and report ﬂags, are automatically 
triggered when users select certain codes. Queries 
are marked in logs and the logs can be viewed and 
accessed centrally by the HIPE & NPRS Unit 
for analysis.
In addition to the edits built into the HIPE computer 
system, approximately 140 validation checks are 
routinely performed on national data by the HIPE & 
NPRS Unit. These cover a range of coding conventions 
and guidelines. If any problems are found, the Unit 
produces query reports for hospitals to verify and 
correct. Routine quality checks are also applied to 
administrative and demographic data in addition 
Using HIPE data as a research and planning 
tool: limitations and opportunities: A Response
The paper by O’Loughlin et al (2005)1 raises a number of issues in regard to the operation 
of the Hospital Inpatient Enquiry that require clariﬁcation and/or a response. In our view, 
there are many potential applications for these data that are not explored in this paper; 
our comments here, however, are of necessity limited to those issues raised by O’Loughlin 
et al (2005) in an attempt to ensure that a more balanced perspective on the operation of 
this system may be portrayed.
USING HIPE DATA AS A RESEARCH AND PLANNING TOOL: LIMITATIONS AND OPPORTUNITIES: A RESPONSE
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to analyses of compliance with the guidelines 
published regularly in Coding Notes3 and the HIPE 
instruction manual
Requests for data quality audits can originate 
from a number of sources, including hospitals, 
the Department of Health & Children, clinicians, 
researchers and staff of the Unit. Audit methodology 
is determined by the purpose of the audit. In-
house auditing software has been developed which 
facilitates extraction of data from the national ﬁle, 
the analysis of data as required and standardisation 
of the format of reports.
In addressing the issue of coverage, O’Loughlin 
et al (2005)1 express concern at “discrepancies 
between the Department of Health and Children’s 
classiﬁcation of an acute hospital and that used by 
HIPE” and list the ﬁve hospitals concerned in Table 
3. It should be noted here that the two hospitals 
not included in the HIPE system opted out many 
years ago. The three hospitals in HIPE considered to 
be long stay or district have been retained within 
the system in the interests of maintaining a data 
ﬂow that might prove useful for the area concerned. 
To put this issue in perspective, however, it should 
be noted that these ﬁve hospitals combined had 
estimated discharges of 5,240 in 2004 while the 
national returns to HIPE for 2004 (estimated end 
Table 1
DATA COLLECTED BY THE HOSPITAL 
INPATIENT ENQUIRY*
ADMINISTRATIVE DATA
• Patient name (retained within hospital)**
• Case reference number and 
hospital number**
• Dates of admission and discharge**
• Dates of ﬁrst and principal procedure
• Day case indicator**
• Admission type and admission source**
• Discharge status and discharge destination**
• General Medical Services status**
• Medical Card Number (GMS patient number)
• Admitting and discharge consultant 
(encrypted)**
• Intensive care days and private care days**
• Public Care days (optional)
• Infant admission weight (for all neonates and 
low weight infants)
• Date of transfer to Pre-Discharge Unit 
(optional)
• Admission Mode
• Waiting List Indicator
CLINICAL DATA
• Principal** and up to 19 secondary diagnoses 
(ICD-10-AM wef 01/01/2005)
• Principal and up to 19 secondary procedures 
(ICD-10-AM wef 01/01/2005)
DEMOGRAPHIC DATA
• Date of birth**, sex**, marital status**
• Area of residence by county**
* Data elements in italics are in addition/
different to the data listing presented in 
Table 1 of O’Loughlin et al (2005)1
** Completion of these data ﬁelds is mandatory
Table 2
SUMMARY OF DATA QUALITY AND CONSISTENCY 
CHECKS INTEGRATED WITHIN THE HIPE SOFTWARE
ITEM
ICD-9-
CM
ICD-10-
AM
Sex checks 1862 1701
Admission type checks 4566 2454
Discharge code checks 6820 4000
Checks on use as Principal Diagnosis/Proceedures 3260 6087
Checks on use as Secondary Diagnoses/Proceedures 216 144
Checks on Age 1664 2213
Checks on LOS 17216 18636
Rare Diagnosis N/A 265
Complete record checks 114 30
Total 35718 35530
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May 2005) were 963,785 discharges. The presentation 
of HIPE data are differentiated by Acute (length of 
stay 0-30 days) and Extended Stay (length of stay > 
30 days) discharges speciﬁcally to take account of 
the fact that a small number of hospitals with long 
stay patients were historically included within this 
system. While the achievement of 100% cover is the 
objective for the HIPE system, the returns to date for 
2004 are at the 96% level.
O’Loughlin et al (2005)1 present as a criticism that 
“HIPE, however, does not record any activity in the 
outpatients or emergency departments”. As noted 
above, this was never an objective put forward 
for the HIPE system. Any decision regarding the 
development of national databases in these areas 
will have to be informed by a range of factors 
including the objectives to be achieved, the costs 
involved and the priorities for such an investment 
given competing alternative demands for scarce 
resources within the health system. Again, to 
gain an appreciation for the scale of such an 
undertaking, it is worth noting that in 2004 there 
were approximately 2.4 million attendances at 
outpatient departments and 1.2 million attendances 
at casualty departments. The range of information 
to be collected, as well as potential applications for 
such data, would have to be addressed before the 
large scale investment of resources in these areas 
could be justiﬁed.
In commenting on completeness of data, O’Loughlin 
et al (2005)1 note that incompleteness can render 
some ﬁelds useless and that one solution is to make 
the entry of data for certain ﬁelds compulsory. They 
neglect, however, to report that this is exactly what 
happens in the HIPE data entry system. In Table 1, 
completion of the data elements marked with a 
double asterisk are treated as mandatory by the 
HIPE data entry system. Records cannot therefore be 
returned to the HIPE & NPRS Unit or included on 
the national ﬁle unless these data ﬁelds have 
been completed.
In the section on data accuracy, O’Loughlin et al 
(2005)1 quote a 1995 study of one Dublin hospital 
and studies of three different conditions. The authors 
do not report on a whole range of initiatives since 
the mid-1990’s including the advancements with 
computer-based edits/checks within the HIPE data 
entry system, improvements in training, support 
and guidelines for coders, or the 18 chart-based 
audits that have been conducted on HIPE data since 
2001. The independent review2 of clinical coder 
training programs and data quality audit procedures 
commissioned from the University of Sydney in 2004 
has also not been referenced or referred to in any 
way by these authors. The Bramley and Reid Report2 
(2004) was funded by the Department of Health 
and Children and commissioned by the ESRI’s HIPE 
& NPRS Unit. A range of objectives were addressed 
by this review including an evaluation of the policies 
and procedures being applied within HIPE for the 
purpose of auditing and improving the quality 
assurance of coded records. A wide ranging set of 
recommendations have been proposed by this report 
and these now constitute an essential input to the 
agenda for the future development of the 
HIPE system. 
The improvement of data quality and the 
development of more effective data quality 
initiatives will always be a challenge for HIPE as 
with other data systems. This objective is, however, 
accorded the highest priority in all developments 
being considered for this system. While recognising 
that much remains to be done, it is also important to 
acknowledge improvements achieved in recent years 
thanks to the commitment of those working at all 
levels within the system and increased investment 
by the Department of Health and Children in the 
HIPE system. When compared with the quality 
assurance initiatives being pursued by an agency 
like the Canadian Institute for Health Information 
(CIHI), those applied within HIPE compare favourably 
as, for example, both HIPE and CIHI support a coding 
query database, an abstracting manual, education 
programmes, abstracting software, system edits and 
re-abstraction studies4,5.
Another important initiative for the HIPE system 
not mentioned by O’Loughlin et al (2005)1 is the 
introduction of ICD-10-AM for morbidity coding 
beginning January 20056. This development followed 
from the conduct of a review of morbidity coding 
schemes internationally and the completion of 
a pilot study in Ireland to determine the best 
available option for use within the HIPE system7. 
As the ICD-9-CM system had been in place since 
1990, the introduction of ICD-10-AM involved the 
implementation of an extensive training programme 
for all clinical coders nationally, together with the 
introduction of such initiatives as the ebook for use 
in coding morbidity data. In addition to updating 
the clinical coding systems to the ICD-10 level, this 
development also provides opportunities for skill and 
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knowledge transfer between the National Centre 
for Classiﬁcation in Health in Australia and the Irish 
HIPE system. Data quality tools used in Australia 
like the Performance Indicators of Coding Quality 
(PICQ) 2004 and the Australian Coding Benchmark 
Audit have already proved to be a useful resource for 
the development of data quality checks and audit 
software within the Irish system.8
Events versus patients
There is no doubt that the inclusion of PPS Number 
on HIPE would greatly enhance the range of 
potential uses for these data. Use of PPS Number is, 
however, currently conﬁned to speciﬁed agencies 
within the public sector and any further extension of 
its use requires legislative provision and consultation 
with the Department of Social and Family Affairs.9 
In the Health Information Strategy there is, however, 
a commitment to the introduction of a system for 
unique identiﬁcation within the health sector using 
PPS Number.9 Delivery on this commitment will, of 
course, have to ensure that the necessary safeguards 
are in place to protect patient privacy.
Socio-economic group variable
When the HIPE system was originally introduced 
in the 1970s, a data variable for occupation was 
included. Prior to the ESRI taking management 
responsibility for HIPE, this variable was regrettably 
dropped in the 1980s due to the very low level of 
response achieved. There is an annual review of 
the data elements collected within HIPE and the 
inclusion of a variable to enable the assignment 
of socio-economic group has been considered on a 
number of occasions. When data changes to the HIPE 
system are considered, however, a number of factors 
have to be taken into account. Firstly, data can only 
be collected for the HIPE system if they are collected 
initially by hospitals. Where a number of changes to 
the system are being considered, priorities must be 
assigned to determine which changes are considered 
more urgent or important. Finally, there is a cost to 
each change to the HIPE system both in terms of the 
workload generated for those collecting and inputing 
the data and also because of software changes 
that have to be made locally and nationally.  While 
the inclusion of a variable to facilitate improved 
measures of socio-economic status remains an 
objective for the HIPE system, the inclusion of 
information on public/private status and medical 
card status should facilitate an assessment of equity 
issues within the system as currently structured.
Small area coding
In the interests of protecting patient and doctor 
conﬁdentiality, the Department of Health and 
Children agreed in the mid 1990s that consultant 
codes would be encrypted and patient name and 
address would not be collected on the national 
database. In the absence of address, it is therefore 
not possible to determine a small area identiﬁer 
for discharges on the HIPE system nationally. 
Given the information held locally on patient 
address, individual hospitals could, of course, 
choose to include a small area identiﬁer on 
their Patient Administration Systems (PAS). The 
recent government announcement regarding the 
development of a post code system would, however, 
be expected to enable some advancement on this 
issue if, when available, the post code of the patient 
can be collected on the HIPE system.
System issues
Access and Conﬁdentiality
In the past, all health boards requesting access to 
HIPE data for their residents have been provided with 
data sets and software to facilitate analysis of these 
data. All health boards have now been provided 
with data sets for their residents and these will be 
updated annually. Comparable, national level data 
can, and have been, provided to health boards and 
other users on request.
Each year, a Shared Information System is developed 
and circulated to all hospitals involved in the national 
casemix programme. This data set includes data that 
the hospitals have agreed to share amongst those 
participating in the programme. Using this system, 
it is therefore possible for an individual hospital to 
benchmark performance against other peer hospitals 
for the same conditions.
Reporting
To date, the resources available to the HIPE system 
have been concentrated on improving coverage, 
quality, timeliness and access to the data. Within 
the HIPE & NPRS Unit at the ESRI, approximately 
1.5 FTEs have been allocated to data management 
and analysis functions. The responsibilities of these 
staff include processing data received from over 60 
hospitals on a monthly basis and preparation of the 
national ﬁle for the Department of Health & Children 
together with report development and responding 
to data requests. In 2004, 119 such requests were 
received from a range of sources including clinicians, 
hospitals, health agencies, government departments, 
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researchers, voluntary organisations etc. Many of 
these requests result in the publication of HIPE data 
in academic journals and other sources. Given the 
constraints on the resources available, combined 
with increasing demands for access to data, it is 
regrettable that it has not been possible for the HIPE 
& NPRS Unit to produce more analytic reports on the 
system. Beginning in 2005, however, the Department 
of Health & Children have made funds available for 
an additional resource to work on data management 
and analysis so it is hoped that within the next year, 
further reports on the system will be available for 
publication.
DISCUSSION
Most of the issues requiring clariﬁcation that are 
summarised in this section, in O’Loughlin et al 
(2005)1, have already been addressed. Just two 
outstanding points remain to be considered. Firstly, 
private hospitals cannot currently be compelled to 
participate in the HIPE system. Private hospitals have 
been invited to be involved in the HIPE system and 
two have agreed to be so involved on a voluntary 
basis. In the interests of completeness for hospital 
activity data at a national level, the inclusion of 
private hospitals in the system is an objective to be 
supported and actively pursued. It is worth noting, 
however, that the largest area of activity in the 
private hospital sector is the provision of maternity 
services and data on all births nationally are collected 
by the National Perinatal Reporting Scheme, also 
managed by the ESRI’s HIPE & NPRS Unit10.
Finally, it seems extraordinary that the only mention 
of the resource requirements for implementing the 
recommendations put forward by O’Loughlin et al 
(2005)1 is in the last sentence of the paper where it 
is noted that “While a signiﬁcant investment will 
be required to implement the recommendations 
arising from this paper, the improved quality 
and quantity of research are likely to make this 
investment worthwhile.” Given competing demands 
for resources across the health system, any request 
for increased investment needs to be quantiﬁed 
and the likely returns estimated if a case for greater 
investment of public funds in health information 
systems is to have any chance of success.
Greater use of HIPE data for research and planning 
is fully supported by all involved in the operation 
and development of this system. It is therefore all 
the more regrettable that, while aspiring to support 
these objectives, O’Loughlin et al (2005)1 present a 
paper that portrays an out-of-date view of the HIPE 
system, criticises HIPE for limitations on functionality 
that are outside the scope of the system objectives 
and puts forward a number of recommendations 
that could not be implemented in the current health 
information environment.
There is no denying that there are deﬁciencies 
with many aspects of the operation of the HIPE 
system. Recognising that the system needs further 
development and improvement need not, however, 
be inconsistent with an appreciation for the many 
improvements introduced within HIPE in recent 
years. A number of these improvements noted 
here, including signiﬁcant developments in quality 
assurance, audit, coder training programmes, 
coverage, completeness, access etc have enhanced 
the value of this system for the many potential 
applications for the data collected. As the only 
source of data on the work undertaken in the most 
expensive part of the health system, it is essential 
that the HIPE system is developed in a stable 
and coherent manner with continued support 
for all involved in all aspects of the system. While 
increased resources will achieve improvements like 
the collection of an expanded range of data and 
improved tools for monitoring data quality, optimum 
data quality standards can only be achieved where 
all involved in data reporting, coding and collection 
are facilitated in taking ‘ownership’ of the data they 
return to the HIPE system.
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CASE REPORT
A 54-year-old male presented to a university 
teaching hospital with a one-week history of 
nausea, vomiting, central abdominal pain and 
increasing abdominal distension. The patient 
was diagnosed as having Crohn’s disease in 1981 
and had undergone a right hemicolectomy for 
complications of the disease one-year following 
diagnosis. Physical examination demonstrated signs 
of dehydration, abdominal distension and central 
abdominal tenderness. Laboratory investigations 
demonstrated a normal haemoglobin, white cell 
and platelet count. Biochemistry and C-reactive 
protein were normal. A plain abdominal radiograph 
showed dilated loops of small bowel. The patient 
was admitted for the management of sub-acute 
small bowel obstruction. This was initially felt to 
be related to adhesions or stricture formation as a 
complication of Crohn’s disease. A nasogastric tube 
was placed and the patient received intravenous 
ﬂuids and intravenous steroids. Contrast-enhanced 
computed tomography (CT) was performed which 
demonstrated proximal small bowel dilatation and 
a large intraluminal ﬁlling defect in the proximal 
ileum (Figure 1). No abnormality was identiﬁed 
in the hepato-biliary tract. Forty-eight hours 
following admission, the patient’s symptoms of 
central abdominal pain recurred. A laparotomy was 
performed which revealed a 7 x 6-cm hard mass in 
the lumen of a segment of proximal ilium affected 
by Crohn’s disease. The enterolith was removed and 
a stricuturoplasty was performed. The patient made 
an uncomplicated postoperative recovery and was 
discharged ﬁve days following surgery.
DISCUSSION
The association between enterolith formation 
resulting in small bowel obstruction in patients 
with Crohn’s disease is a very uncommon clinical 
entity.1 In patients with Crohn’s disease, enterolith 
Small bowel obstruction secondary to a giant 
enterolith complicating Crohn’s disease
ABSTRACT 
Background  Enterolith formation associated with Crohn’s disease is a very uncommon 
clinical entity. 
Aim To describe a case of sub-acute small bowel obstruction secondary to a giant 
enterolith in a patient with Crohn’s disease. 
Results  A 54-year-old male with a history of Crohn’s disease presented with sub-acute 
small bowel obstruction secondary to a giant enterolith. The diagnosis was 
conﬁrmed utilising plain ﬁlm radiography and computed tomography.
Conclusion  Plain ﬁlm radiography and computed tomography play a central role in 
establishing the diagnosis of this rare complication of Crohn’s disease and assist in 
planning surgical intervention.
Figure 1 (a) —
CONTRAST-
ENHANCED 
COMPUTED 
TOMOGRAPHY 
DEMONSTRATES 
SMALL BOWEL 
OBSTRUCTION 
SECONDARY TO A 
LARGE ENTEROLITH.
Figure 1 (b) — 
SMALL BOWEL 
FOLLOW THROUGH 
EXAMINATION 
DEMONSTRATES 
AN  INTRALUMINAL 
FILLING DEFECT 
SECONDARY TO A 
LARGE ENTEROLITH.
1(a) 1(b)
SMALL BOWEL OBSTRUCTION SECONDARY TO A GIANT ENTEROLITH COMPLICATING CROHN’S DISEASE
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formation may occur within a pre-stenotic segment 
of bowel affected by regional enteritis. The presence 
of an enterolith in patients with Crohn’s disease may 
be the ﬁrst manifestation of chronic inﬂammatory 
complications of regional enteritis.2 Complications 
of enterolith formation in this clinical setting include 
abcess formation and bowel perforation. Enteroliths 
causing small bowel obstruction may closely 
resemble gall stone ileus as a clinical entity and 
should be considered in the differential diagnosis.
Plain radiographs will demonstrate features of small 
bowel obstruction and may show the presence 
of lamellated calciﬁcations within the enterolith. 
Ultrasound may demonstrate the presence of 
highly echogenic intraluminal mass with acoustic 
enhancement. The ﬁndings on contrast-enhanced 
computed tomography (CT) of this condition may 
mimic a small bowel intussusception. The preferred 
management of this rare complication of Crohn’s 
disease is only available from few case reports. 
If conservative management is unsuccessful, 
manual destruction and “milking” of the shattered 
obstructing enterolith down to the colon has been 
advocated as the least invasive surgical method. 
If this is unsuccessful, an enterotomy may be 
performed, preferably at a point remote from the 
site of obstruction, in order to make an incision in 
a non-inﬂamed segment of bowel. If a complicated 
enterolith is present, resection of the diseased 
segment of bowel is necessary.3
CONCLUSION
Enterolith formation associated with Crohn’s 
disease is a very uncommon clinical entity. Plain 
ﬁlm radiography and computed tomography play a 
central role in establishing the diagnosis of this rare 
condition and assist in planning surgical intervention.
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INTRODUCTION
Cystic lesions of the liver can be classiﬁed into 
four main groups based on aetiology: congenital, 
neoplastic, inﬂammatory and traumatic. Congenital 
liver cysts are the most commonly encountered, 
and include simple cysts and polycystic liver 
disease. Primary cystic neoplasms of the liver 
are rare, and include biliary cystadenomas and 
cystadenocarcinomas. Inﬂammatory liver cysts 
are associated with an infectious aetiology from 
bacterial and parasitic origin, such as hydatid cysts. 
Traumatic cysts occur following a signiﬁcant injury 
resulting in subcapsular haematoma formation, or 
disruption of the intrahepatic biliary tree.
The majority of cases of congenital liver cysts 
are asymptomatic. They are usually discovered 
incidentally on radiological imaging, or rarely 
when they become symptomatic. We present an 
unusual case of a young female who presented 
with obstructive jaundice due to a centrally located 
giant non-parasitic cyst of the liver. The aetiology 
and management of this uncommon problem are 
discussed.
CASE REPORT
A 25-year-old female presented with a three-
week history of epigastric discomfort, dyspepsia, 
abdominal bloating, and jaundice. On further 
questioning she had noticed a fullness in her right 
upper abdomen over the previous nine months. 
She had no history to suggest biliary colic or 
ascending cholangitis. She denied weight loss. On 
examination, she was jaundiced. Her vital signs 
were normal. A large tender mass was palpable in 
the right upper quadrant. Investigations conﬁrmed 
cholestatic liver function tests with an elevated 
serum bilirubin (290μmol/L), a low serum albumin 
(29g/L) and an abnormal coagulation proﬁle with 
an INR of 1.4. An abdominal computed tomography 
(CT) scan demonstrated a massive centrally located 
liver cyst compressing the liver parenchyma with 
hilar obstruction (Figure 1). The right kidney was 
displaced downwards into the pelvis (Figure 2). 
Hydatid serology was negative. At laparotomy, a 
massive central liver cyst containing a mixture of 
cyst ﬂuid and old haematoma was demonstrated 
with atrophy of both hepatic lobes (Figure 3). 
A total cystectomy and cholecystectomy was 
performed with excision of redundant liver folds. An 
intraoperative cholangiogram demonstrated normal 
biliary anatomy.  The histology was consistent with 
a solitary bile duct cyst. A repeat abdominal CT scan 
four weeks later demonstrated rapid regeneration 
of the liver with a small collection at the site of cyst 
removal. On follow-up she remains well, with no 
evidence of cyst recurrence.
DISCUSSION
Simple cysts of the liver are usually asymptomatic, 
and detected incidentally during abdominal 
imaging. They are thought to arise due to aberrant 
development of intrahepatic bile ducts, and usually 
do not communicate with the biliary ductal 
system. Simple cysts can be single or multiple, 
and range in size from millimetres to >20cm in 
diameter. Symptoms are rare, but can occur if the 
cyst becomes complicated as a result of intracystic 
bleeding, rupture, or secondary bacterial infection. 
Compression of adjacent structures can occur 
including compression of the inferior vena cava 
causing lower extremity oedema, compression of 
the portal vein resulting in portal hypertension, 
or compression of the biliary tree resulting in 
Giant solitary non-parasitic cyst of the liver
ABSTRACT 
Background  Cystic diseases of the liver and intrahepatic biliary tree are uncommon. The 
majority of cases are detected only when patients become symptomatic, or as an 
incidental ﬁnding on radiological imaging. 
Methods  We discuss the case of a 25-yr-old female with a centrally located giant liver cyst 
causing obstructive jaundice, and brieﬂy discuss the management options in the 
treatment of this uncommon problem.
Results and Conclusions  Intervention is recommended in patients with symptomatic 
simple cysts of the liver. Surgical cystectomy is the treatment of choice for large 
deep seated cysts.
GIANT SOLITARY NON-PARASITIC CYST OF THE LIVER
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Figure 1 —
AXIAL CONTRAST-
ENHANCED 
COMPUTED 
TOMOGRAPHY SCAN 
THROUGH THE 
UPPER ABDOMEN, 
DEMONSTRATING A 
GIANT CENTRALLY 
LOCATED LIVER CYST 
COMPRESSING THE 
HILAR STRUCTURES.
Figure 2 —
AXIAL CONTRAST-
ENHANCED 
COMPUTED 
TOMOGRAPHY 
SCAN THROUGH 
THE PELVIS, 
DEMONSTRATING 
INFERIOR 
DISPLACEMENT OF 
THE RIGHT KIDNEY.
Figure 3 — 
AT LAPAROTOMY, A 
GIANT LIVER CYST IS 
DEMONSTRATED.
cholestasis. Only 16 cases of enlarging non-
haemorrhagic simple liver cysts causing obstructive 
jaundice have been reported in the English literature, 
most of which were centrally located.1-3 Other 
possible presentations include rupture into adjacent 
bowel or biliary tree, or development of carcinoma. 
Treatment is recommended only in symptomatic 
patients. Management options include aspiration, 
aspiration and injection of a sclerosing agent 
into the cyst cavity (absolute alcohol, minocycline 
hydrochloride or doxycycline), fenestration 
(laparoscopic or open) with marsupulization, total 
cystectomy, hepatic resection and orthotopic 
transplantation.
Simple percutaneous aspiration is associated 
with risk of infection, and recurrence is invariable. 
Aspiration and percutaneous instillation of a 
sclerosant has been demonstrated to be safe and 
effective.1,2,4 However, multiple treatments may be 
required to achieve resolution and there is a high 
risk of recurrence. This method is contraindicated if 
the cyst communicates with the biliary tree, when 
hydatid disease is suspected or in the presence 
1 2
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of malignancy. Fenestration can be performed if 
>50% of the surface area of the cyst is superﬁcial. 
Laparoscopic fenestration can be carried out 
successfully for superﬁcial cysts located within the 
anterior liver segments (segments III, IV, V, VI). It is of 
limited value where the cyst is located in segments 
VII or VIII, as adequate drainage would be difﬁcult 
to achieve. If >50% of the surface area of the cyst 
remains, or the majority lies within the hepatic 
parenchyma, ablation of the residual cyst lining 
by direct cautery, argon beam coagulation, topical 
sclerosant, or omentoplasty may reduce the risk 
of recurrence.1 Small cyst cavities can persist, and 
recurrences do occur.
In the case of giant liver cysts, the resultant ﬂuid loss 
and secretion following cyst fenestration can exceed 
the resorptive capacity of the peritoneal surface 
resulting in ascites. Surgical cystectomy has been 
recommended as the treatment of choice for giant 
deep seated liver cysts.3-5 However, this procedure 
is hazardous due to an increased risk of injury in 
the presence of distortion of large vessels and bile 
ductal elements traversing a thin compressed liver 
parenchyma. Postoperatively, synthetic function of 
the liver may be compromised, and recovery can be 
prolonged. Partial hepatectomy may be indicated 
in the treatment of complex recurrent cysts, the 
localised form of Caroli’s syndrome, and type III 
polycystic liver disease.5,6
Biliary cystadenomas are rare neoplasms, and 
patients usually present with non-speciﬁc 
symptoms. The majority of cases occur in middle-
aged women. An abdominal CT, or ultrasound 
demonstrating a thick walled or multiloculated cyst 
with solid intracystic components should raise a 
suspicion for a cystic neoplasm. Neither preoperative 
imaging nor histology can reliably distinguish biliary 
cystadenoma or cystadenocarcinoma. Because of 
the risk of malignancy and the inability to accurately 
determine tumour type preoperatively surgical 
resection is recommended.
CONCLUSION
Intervention is recommended in patients with 
symptomatic simple cysts of the liver. Surgical 
cystectomy is the treatment of choice for large 
deep seated cysts. This case illustrates the mode of 
presentation, and management options in a young 
patient with a symptomatic giant non-parasitic cyst 
of the liver.
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CASE REPORT
We report a 21-year-old female who presented to the 
Accident and Emergency Department with a 14-hour 
history of colicky epigastric pain and vomiting. Of 
note in her background she had a biopsy of a benign 
abdominal tumour aged 3 years. On examination 
she was tender in the epigastrium, and an ill-deﬁned 
mass could be palpated extending from the pelvis 
to above the umbilicus. Vital signs were normal, 
as was her white cell count. CA125, CA19.9, and 
alphafetoprotein were all within normal limits. A 
plain ﬁlm of abdomen revealed a huge mass that 
displaced dilated loops of small bowel into the upper 
abdomen (Figure 1). CT of abdomen showed a 26cm 
x 13cm complex soft tissue mass originating from 
the retro-peritoneum and occupying most of the 
abdomen and pelvis (Figure 2). It encased the aorta 
and inferior vena cava, both of which were pushed 
anteriorly. One small area of calciﬁcation was seen. 
There was no evidence of intra-spinal involvement. 
A working diagnosis of small bowel obstruction was 
made and the patient was treated conservatively.
She had previously presented as a 3-year-old with 
a large abdominal mass. Laparotomy and open 
biopsy were performed, but no attempt was made 
to resect the tumour. Histology then showed a 
ganglioneuroma. She was followed-up with serial 
ultrasound, until she was lost to follow-up at the age 
of twelve.
On this occasion ultrasound-guided percutaneous 
biopsy was performed and histology showed mature 
ganglion cells (Figure 3), which strongly expressed 
neuroﬁlament markers and were Bielschowsky silver 
positive. Some of the ganglion cells were binucleate, 
and surrounded by mature perineurial cells as well 
as well-developed axons. There were no primitive 
cells and no necrosis. The cell proliferation index 
(as judged by MIB 1 immuno-labelling) was very 
low (<1%), consistent with benign ganglioneuroma. 
The original biopsy was reviewed, and showed 
almost identical features. A 24-hour urine collection 
showed elevated dopamine excretion, while other 
catecholamines were within normal limits (Table 1). 
Clinical examination and radiological investigation 
failed to detect any metastasis.
The patient’s symptoms failed to resolve with 
conservative treatment and she underwent a 
laparotomy, at which a massive intra-abdominal 
tumour was found (Figure 4), displacing small and 
Massive retroperitoneal ganglioneuroma 
presenting with small bowel obstruction 18 
years following initial diagnosis
ABSTRACT 
Background  Ganglioneuroma is a rare tumour of neural crest origin, which arises from 
maturation of a neuroblastoma. While previously considered to be non-functioning, 
they are now known to be frequently endocrinologically active. 
Aims and Methods  We report a case of a massive retroperitoneal ganglioneuroma 
presenting with small bowel obstruction in an adult, 18 years after initial diagnosis. 
Urinary dopamine levels were elevated, but other catecholamines were within 
normal limits. This is the ﬁrst report in the English-language literature of a 
retroperitoneal ganglioneuroma presenting with or causing intestinal obstruction. 
We also review the metabolic, radiological, and histological features of these 
tumours. Relevant publications were identiﬁed from a Medline search using the 
MeSH headings ‘ganglioneuroma’, ‘retroperitoneal neoplasms’ and ‘intestinal 
obstruction’, and also from the reference lists of retrieved articles.
Conclusions  Ganglioneuroma can grow to a massive size and present in a varied manner. 
It should be included in the differential diagnosis of any large retroperitoneal or 
mediastinal mass, including those causing bowel obstruction.
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large bowel proximally. An adherent segment of 
small bowel was non-viable and a partial small 
bowel resection with primary anastomosis were 
performed. Whilst bowel function was slow to 
return to normal, her in-hospital stay remained 
complication-free.
DISCUSSION
Ganglioneuroma represents the benign end 
of the spectrum of primitive neuroepithelial 
tumours, which also includes neuroblastoma 
(highly malignant) and ganglioneuroblastoma 
(intermediate). Geographical or racial predilection 
is not reported in the literature, although 
ganglioneuroma is more commonly diagnosed 
in countries such as Japan where infants are 
screened for neuroblastic tumours. There appears 
to be no gender preference.1 Neuroblastoma and 
ganglioneuroblastoma represent the second most 
common group of solid extra-cranial neoplasms 
of infancy and childhood.2 They account for 
approximately 8% of malignancies in these age 
groups.3 They may be found in association with 
a number of syndromes including Beckwith-
Wiedemann, von Recklinghausen’s disease, 
Hirschprung’s disease, opsoclonus-myoclonus, 
heterochromia iridis, watery diarrhoea or Cushing’s 
syndrome.4 They arise from neural crest cells 
and occur more commonly in the mediastinum, 
retroperitoneum and adrenal glands, with 
occasional cases reported in the neck or spinal 
canal.5 The differentiation of neuroblastoma 
into ganglioneuroma is well-described and is 
more common in younger patients6,7, but most 
tumours arise de novo. Much less commonly, 
malignant transformation of ganglioneuroma into 
neuroblastoma is described in the adult.8
The presentation of neural crest tumours varies 
greatly, from asymptomatic tumours discovered 
incidentally on imaging studies or mass screening, 
to a palpable mass, scoliosis, neurological symptoms 
or even respiratory distress.9 To our knowledge, 
there are no reports in the English-language 
literature of retroperitoneal ganglioneuroma 
presenting with or causing small bowel obstruction. 
Neuroblastoma staging systems can also be 
applied to ganglioneuroma: using the International 
Neuroblastoma Staging System10 our patient’s tumour 
was Stage 3, as it was a unilateral tumour inﬁltrating 
across the midline. In general ganglioneuromas may 
be treated by complete excision, however in the case 
described the tumour was unresectable.
Although catecholamine secretion is common in 
neuroblastomas, ganglioneuromas were formerly 
thought to be endocrinologically inactive. However, 
one series of 46 patients found elevated plasma 
or urinary catecholamines in 39%.1 Another series 
of 25 patients found a trend for metabolic activity 
to correlate with tumour size.11 Ganglioneuromas 
have rarely been reported as being VIP-secreting, 
when they are frequently associated with severe 
watery diarrhoea.12 123I-mIBI uptake has also been 
well described in ganglioneuroma, tending to occur 
in functionally active tumours.1 On this occasion 
scintigraphy was not required for diagnosis.
CT is the radiological investigation of choice when 
establishing the diagnosis of ganglioneuroma, as 
the appearances can be characteristic and are well 
described.13,14 In this case, ﬁndings were consistent 
with those previously reported: that of a round 
or oval tumour encasing the great vessels with or 
without calciﬁcation and a tumour capsule. Where 
intra-spinal involvement is suspected, MRI should be 
performed as it is superior to CT in this regard.13
Ganglioneuroma is a benign neoplasm consisting of 
relatively mature ganglion cells arranged in groups, 
surrounded by a Schwann cell-rich stroma. They are 
most commonly asymptomatic. Less than 30% are 
adrenal in origin, the remainder are located in the 
posterior mediastinum, retroperitoneum or other 
sites15 including the small and large intestine.16 
The gross appearance is usually of a sharply 
circumscribed mass without a true capsule and a 
cut surface, which is grey/tan with some gelatinous 
ﬁrm and whorled regions. At light microscopy, 
ganglioneuromas have a variable number of mature 
ganglion cells. The cells may be binucleate and 
misshapen. The stroma consists of Schwann cells and 
variable amounts of collagen. Immunohistochemical 
identiﬁcation of neuroﬁlament and S100 is useful in 
the diagnosis and the cell proliferation index marker
Table 1
24-HOUR URINARY CATECHOLAMINE COLLECTION
NMOL PER 24 HRS
NORMAL RANGE 
(NMOL PER 24 HRS)
Dopamine 7376 653-2700
Adrenaline 25.6 27-100
Noradrenaline 208 118-500
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Mib, as judged by Ki 67 immunolabelling, is a useful 
indicator of cell turnover. It is of interest that in this 
tumour there was no change in either maturity 
or cell proliferation index in either biopsy, despite 
an eighteen-year interval between the two. The 
Shimada classiﬁcation is widely used to determine 
the degree of differentiation in neuroblastic 
tumours.10 The most malignant is a stroma-poor 
neuroblastoma of undifferentiated subtype whilst 
the most benign is ganglioneuroma, which is devoid 
of any undifferentiated subtype. The classiﬁcation 
has prognostic signiﬁcance, as do other biological 
characteristics such as presence or abscence of 
chromosome 1p, ploidy, and MYCN ampliﬁcation.
Ganglioneuroma is a rare benign tumour of the 
mediastinum, retroperitoneum and other tissues, 
which can grow to a massive size and present in a 
varied manner. It should be included in the differential 
diagnosis of any large mediastinal or retroperitoneal 
mass, including those causing bowel obstruction. 
Management involves total excision where possible, 
while inoperable tumours such as that described 
above must be managed conservatively.
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Dear Editor 
In recent years the use of Troponin testing to 
monitor myocardial damage has become more 
pervasive and prominent, replacing the old style CK-
MB measurement. Troponin elevation is a marker 
of cardiac injury and high risk, it is also raised in 
a minority of acute coronary syndrome patients. 
However, it is important for clinicians to realise that 
a single rise in Troponin levels is of indeterminable 
signiﬁcance. An appropriate series of tests over 
time, ﬁtting in with the right clinical picture is of 
most value. The Troponin complex in striated muscle 
ﬁbres has three distinct subtypes and c-troponin-I 
is believed to be the one present only in cardiac 
muscle. Consequently, c-troponin-I is released when 
there is an assault to the myocardium and this is 
what laboratory testing picks up, (some labs may 
measure the troponin-T sub unit, this however has 
been found to be less speciﬁc and less sensitive). 
Interpretation of results can be confusing and there 
are several caveats to be aware of. A positive c-
troponin-I level means that cardiac muscle contents 
have leaked out of cells. The primary reason why this 
occurs is in response to injury. There are multiple 
causes of cardiac muscle injury that includes acute 
coronary events, but there is also a whole spectrum 
of disorders that can cause a rise in troponin. The 
largest study of this subject1 showed that all of the 
following were associated with elevated c-troponin-
I levels. Pulmonary embolism2 congestive cardiac 
failure, cardiomyopathy, myocarditis, rhabdomyolosis, 
chest contusions, sepsis, mural thrombi, prosthetic 
heart valves, neoplasms, radiation-induced coronary 
stenosis, homcystinuria, SLE and 3 rheumatoid 
arthritis. Surprisingly, high troponin levels have also 
been found in Cocaine abusers and marathon runners.
Some of these are obviously signiﬁcant while 
others merely represent a normal response to a 
physiological event. C-troponin-I can therefore be 
distinctly elevated in many ‘non-cardiac’ disorders. 
The rise is evidence of cardiac damage per se and the 
relative importance of this should be determined 
by the state of the patient. The Troponin test is a 
valuable and sensitive one but always needs to be 
assessed in the cold light of the clinical scenario as 
its speciﬁcity to acute coronary syndromes can be 
questionable, especially on a one-off basis.3 Perhaps 
the advancement of this ultimate biochemical test 
leads us round in full circle when we attempt to clarify 
its rise. That is, to a thorough clinical history taking.
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Dear Editor
Archimedes famously made observations about 
buoyancy during ‘hydrotherapy’ – after which he ran 
naked from his bath proclaiming ‘Eureka!’1 We have 
made our own observation on the relationship of 
buoyancy and bone density.
A 78-year-old frail lady was receiving inpatient 
rehabilitation including hydrotherapy for 
osteoarthritis, which curtailed independent living. 
At the ward round, the physiotherapist reported 
particular difﬁculties with the patient’s therapy 
because of ‘osteoporosis’. Assuming that now even 
trained staff members were confusing the terms 
osteoarthritis and osteoporosis, the therapist was 
challenged to explain. “She was difﬁcult to manage 
in the hydrotherapy pool,” she replied – “because 
she ﬂoats.” Subsequent bone density measurement 
conﬁrmed severe osteoporosis with Z-scores (T-
scores) of -1.7 (-3.6) at the femoral neck and -2.9 (-5.0) 
at the lumbar spine. 
This interesting clinical observation demonstrates 
the Archimedes principle: an object immersed in 
ﬂuid will ﬂoat if it is less dense than the ﬂuid.1 The 
human skeleton contributes approximately 20% 
to total body weight. It would be naive to assume 
a direct correlation between bone density and 
buoyancy, as other factors including fat and muscle 
bulk are also relevant but clearly physiotherapists 
delivering hydrotherapy have spotted a relationship. 
An increased awareness of osteoporosis in all staff 
is vital as insufﬁciency fractures cause increased 
morbidity and mortality. Novel strategies to 
heighten awareness of osteoporosis have included 
recruiting hairdressers in Manchester.2,3 In this 
case, vigilant physiotherapist identiﬁed a patient 
with osteoporosis that might otherwise have been 
overlooked.
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125 Years of Caring in Dublin
Our Lady’s Hospice, Harold’s Cross 1879-2004
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DublinSince its foundation in 1879, Our Lady’s Hospice has 
been an intimate part of the lives of the people of 
Dublin. Dr. Tim Healy has chosen to write a history 
that captures the foundation of Our Lady’s Hospice 
by the Religious Sisters of Charity, and traces its 
evolvement into a modern centre that delivers 
geriatric, rheumatology and palliative care to the 
people of Dublin and beyond. Using internal records 
from the hospice and interviews from current and 
retired staff, he eloquently captures this transition.
The Hospice for the Dying (title until 1969) was 
founded in response to the suffering of patients 
in 19th century Dublin. In the early chapters of 
the book, Dr. Healy captures the meagre social 
conditions and attitudes that existed in Dublin, 
which lead initially to the establishment of a 40-
bedded unit at Our Lady’s Mount. Many hospitals 
at that time had a policy of refusal of admission for 
patients who were beyond hope of recovery and 
the hospice would have provided a place of care for 
these people. Earliest admissions to the hospice 
consisted mainly of tuberculosis patients who were 
offered a ‘clean bed and a faint smell of soap and 
carbolic’. The Sisters worked long hours but delivered 
care in a cheerful and pleasant manner. The last case 
of tuberculosis was admitted to the hospice in 1958. 
Cancer replaced tuberculosis as the main reason 
for admission in the latter half of the 20th century. 
Scattered throughout the book are anecdotal tales 
of patients and staff, which gently reminds us of the 
humanity and suffering of the people who came in 
contact with the Hospice. 
This is a comprehensive and historically rich text and 
easily readable. Dr. Healy in a narrative style reminds 
us that the present-day delivery of holistic care to 
patients by a large multi-disciplinary team is deeply 
rooted in the type of care delivered by the Sisters in 
the previous century. This text provides readers with 
an insight into one of the great institutions of Dublin 
and would interest anyone whose life has been 
touched by the care offered there.
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A Life in Medicine
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From happy childhood and pleasant schooldays with 
the Christian Brothers in Monaghan  to impecunious 
student life in University College Dublin, Malachy 
Smyth graduated to the wards of English hospitals 
just in time to be called up for service with the 
Royal Air Force in Africa and the Middle East, most 
memorably in a detention camp after Rommel’s 
defeat at El Alamein. A study grant brought him to 
the Royal College of Surgeons in Edinburgh, followed 
by marriage to Lucy O’Hara of Sligo in 1952, and 
surgical training in Hull and Leeds. Toronto and Utica 
in upstate New York beckoned, and so successful was 
his orthopaedic practice that he was appointed to 
the Workers Compensation Board, which eventually 
became his sole source of income when he could 
no longer afford insurance costs. Even so, life was 
pleasant with golﬁ ng weeks in Florida, until Lucy’s 
stroke made them decide to return to Ireland in 1994 
to Rosses Point where her father had left her some 
land. When she died in 1999 Malachy moved back to 
live with his married brother in Monaghan.
‘A Life’, in fact, is a ghosted autobiography with a 
difference: the ghost materialises as the author 
who fails to curb the third-person egocentricity. 
The retired doctor dredged his memory banks 
enthusiastically for Aubrey Malone but advised him 
not to worry too much about chronology. Taking him 
at his word perhaps was not the wisest choice to 
make. The kernel of the story is the work with Verna 
Wright at Leeds on prolapsed discs published in 
Journal of Bone and Joint Surgery (1958; 40A: 1401). 
The paper’s introductory sentences about deciding 
to test the ‘well established clinical syndrome’ 
associating sciatic pain with herniation of a vertebral 
disc seem to have been forgotten or mislaid in the 
biography. A few days after operation, taking up the 
slack in a nylon loop which had been passed around 
the freed spinal root could rekindle the preoperative 
pain; the patients, who ‘took a co-operative and 
intelligent part’ in the procedure, were
suitably impressed.
Malachy had the unique pleasure of serendipitously 
discovering that the paper had been reprinted as a 
classic in Clinical Orthopaedics and Related Research 
(1977; 129: 9). And because the wrong M J Smyth 
had been identiﬁ ed in the eulogy, he had the rare 
distinction of being able to say with Mark Twain that 
the rumour of his death was greatly exaggerated. 
But the accolade seems to have been celebrated 
with heady wine, for he has adopted a proprietorial 
role over pain, in all its manifestations, regardless of 
Bonica, Wall and Melzack. Two hundred years after 
the Galvani-Volta controversy, he muses about ‘what 
kind of electricity comes from a nerve end’, unaware 
that the Nobel Prize in 1991 went to Neher and 
Sakmann for the answer.
With chronology the surgeon must also have implied 
accuracy and precision. So scarlet are the misprints 
that one wonders if the proofs were read. As a result 
this is the story of a life well lived but not well written.
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This well-researched, well-argued and well-expressed 
report paints a picture only too familiar both to those 
seeking sexual and reproductive health services and to 
those trying to provide them.
 
This report came about following regular meetings 
between the Transgender Equality Network Ireland 
and the Equality Authority. It addresses the health 
services provisions for transsexuals in Ireland, including 
differences across health board areas. It documents 
transsexual people’s perspectives on access to health 
services and makes recommendations based on these 
ﬁ ndings.
A chapter describing the increasing international 
recognition of transsexualism as a medical condition 
requiring speciﬁ c treatments and the increasing legal 
recognition of gender change shows how far we have to 
go in Ireland to catch up.
In addressing the health service provisions in Ireland 
feedback was obtained from the health boards and from  
relevant professional medical bodies such as the Irish 
College of Psychiatrists. This revealed that policy and 
practice around the health needs of transsexual people 
is underdeveloped. In particular: most health boards 
focussed on access to genital reassignment surgery 
abroad; there appeared to be little or 
no particular experience or expertise in 
meeting the needs of transsexual people 
and there did not appear to be procedures 
for onward referral to specialist services.
Seventeen transsexual people 
participated in the research. Their 
perspectives on doctors’ and counsellors’ 
responses to their needs are described. 
These include negative reactions, lack 
of knowledge about the condition 
and lack of knowledge of specialised 
services. These responses caused anxiety, 
despondency and depression. Where 
respondents did eventually manage to 
access appropriate services the impact 
was always positive.
All involved in this report have helped 
to lift the veil of ignorance, prejudice and indifference in 
relation to transsexualism. This report could go a long way 
in convincing health professionals to take transsexual 
people more seriously and to work together to improve 
services. Perhaps even those who do not “believe” in the 
condition will at least be persuaded to refer transsexual 
people to those who do.
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APPLICATION FIELD
The Gagna A. & Ch. Van Heck Prize is awarded to a 
researcher or physician whose work has contributed 
to the treatment of a currently incurable disease, or 
has signiﬁ cantly contributed to research into such an 
outstanding progress.
AMOUNT The Prize will amount to 75,000 Euro.
NOMINATIONS
This triennial and international Prize, awarded for the 
second time in 2006, is reserved for a work submitted 
by one or two researcher(s).
Nominations must be received by the Secretary general 
of the National Fund for Scientiﬁ c Research, F.N.R.S., rue 
d’Egmont 5, BE - 1000 Brussels, Belgium, by Oct. 3, 2005.
The person proposing the nomination must provide a 
memorandum in English on the candidate’s merits.
REGULATIONS
The complete regulations can be obtained from the 
secretariat of the F.N.R.S., rue d’Egmont 5, BE - 1000 
Brussels, Tel.: 32 (0) 2.504.92.11,
Tel. Prize: 32 (0) 2.504.92.40, Fax: 32 (0) 2.504. 92.92,
e-mail: mairesse@fnrs.be, website: www.fnrs.be
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